The original disclosure in Japanese was released on May. 12, 2022 at 16:30 (GMT+9)

Consolidated Financial Statements for the Year Ended March 31, 2022
FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (PRIME section)
Code number: 2531
URL: https://www.takara.co.jp/
Company representative: Mutsumi Kimura, President
Contact: Masakazu Usami, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124

Annual statement filing date (as planned): Jun 29, 2022

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the year ended March 31, 2022 (April 1, 2021 - March 31, 2022)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ended March 31, 2022		Year ended March 31, 2021	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	300,918	8.1	278,443	(1.0)
Operating income (loss)	43,354	100.8	21,595	36.4
Ordinary income (loss)	43,230	97.1	21,929	34.8
Net income (loss) attributable to owners of the parent	20,769	96.4	10,574	17.7
Net income (loss) per share (Yen)	105.05		53.48	
Fully diluted net income per share (Yen)	-		-	
Return on equity		12.3		6.9
Ordinary income to total assets ratio		12.9		7.4
Operating income to net sales ratio		14.4		7.8
Note: Comprehensive income (loss)	39,992	145.0	16,320	152,3
(Reference) Income (loss) from equity method investment	46		123	

Since the "Accounting Standard for Revenue Recognition" (Corporate Accounting Standard No. 29 , March 31, 2020), etc. has been adopted from FY2022, the above results is the amount after applying the accounting standard.

(2) Consolidated financial position

	As of March 31, 2022	As of March 31, 2021
	(Millions of yen)	(Millions of yen)
Total assets	362,438	306,918
Net assets	224,555	191,535
Equity ratio (%)	49.8	51.1
Net assets per share (Yen)	912.58	793.53
(Reference) Equity	180,420	156,884

(3) Consolidated Cash flow

	Year ended March 31, 2022	Year ended March 31, 2021
	(Millions of yen)	(Millions of yen)
Cash flow from operating activities	16,376	27,100
Cash flow from investing activities	(10,399)	(6,738)
Cash flow from financing activities	4,133	(1,506)
Cash and cash equivalents, end of year	75,729	62,860

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2021	Year ended March 31, 2022	Year ending March 31, 2023 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	21.00	37.00	29.00
Annual	21.00	37.00	29.00
Total dividend (Millions of yen)	4,151	7,315	
Payout ratio (%)	39.3	35.2	35.8
Dividend on equity (%)	2.7	4.3	

Note: Correction of dividend forecast from the most recent dividend forecast: Yes

3. Forecast for the year ending March 31, 2023 (April 1, 2022 - March 31, 2023)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2022		Year ending March 31, 2023	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	146,000	3.4	301,000	-
Operating income (loss)	15,000	(30.6)	30,000	(30.8)
Ordinary income (loss)	15,400	(29.6)	30,400	(29.7)
Net income (loss) attributable to owners of the parent	8,100	(19.4)	16,000	(23.0)
Net income per share (Yen)	40.97		80.93	

Note: Correction of financial forecast from the most recent financial forecast: Yes

4. Others

(1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation): No

(2) Changes in accounting policies, accounting estimates and retrospective restatement
1) Changes based on revisions of accounting standard: Yes
2) Changes other than ones based on revisions of accounting standard: No
3) Changes in accounting estimates: No
4) Restatement: No

(3) Number of outstanding shares (common stock)
1) Number of outstanding shares at year end (Treasury stocks are included):
As of March 31, 2022 199,699,743 shares
As of March 31, 2021 199,699,743 shares
2) Number of treasury stocks at year end:
As of March 31, 2022 1,995,577 shares
As of March 31, 2021 1,995,468 shares
3) Average number of outstanding shares:
Year ended March 31, 2022 197,704,189 shares
Year ended March 31, 2021 197,704,467 shares

Contents of the attached document

1. Overview of Financial Results……... 2
(1) Overview of Financial Results for the Fiscal Year under Review……..…… 2
(2) Overview of Financial Position for the Fiscal Year under Review…… 7
(3) Overview of Cash Flows for the Fiscal Year under Review……..……..… 7
(4) Future Outlook……...……..… 7
2. Basic Concept on Selection of Accounting Standards…..……..…… 8
3. Consolidated Financial Statements and Primary Notes…...……...…… 9
(1) Consolidated Balance Sheets……...…… 9
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income……...…… 11
Consolidated Statements of Income……..…… 11
Consolidated Statements of Comprehensive Income.……. 12
(3) Consolidated Statements of Changes in Net Assets……. 13
(4) Consolidated Statements of Cash Flows…….. 15
(5) Notes to Consolidated Financial Statements…… 16
(Notes on Premise of Going Concern)..…….. 16
(Changes in Accounting Policies).……. 16
(Segment Information).…….. 16
(Revenue Recognition)…….. 19
(Per Share Information).…… 20
(Significant Subsequent Events).……... 20

○Supplement for the Consolidated Financial Statements

1. Overview of Financial Results

(1) Overview of Financial Results for the Fiscal Year under Review

In the fiscal year under review, ended March 31, 2022, the Japanese economy faced a slow recovery in personal consumption amid the prolonged effects of COVID-19 infections, and the outlook became increasingly uncertain mainly due to soaring raw material prices and the rapid depreciation of the yen toward the end of the fiscal year. Overseas, although there are regional differences, restrictions on activities due to COVID-19 infections have eased and economic activities are expected to recover; however, the economic outlook remains difficult to predict due to prolonged trade friction between the U.S. and China, disruptions in the global supply chain caused by Russia's invasion of Ukraine, and soaring resource prices.

Under these economic circumstances, the Group has endeavored at the Takara Group Medium-Term Management Plan for FY2021-2023, which serves as the first step in the Group's action plans cited in its long-term management vision, TaKaRa Group Challenge for the 100th, announced in May 2020. The Group has been allocating and investing management resources in areas that should be strengthened, and has been focusing on rebuilding business structures and global corporate functions that consistently generate various forms of value that enhance profitability, while keeping a close eye on the impact of COVID-19 and flexibly addressing environmental changes.

As a result, in the fiscal year under review, ended March 31, 2022, net sales were up 8.1% year on year to ¥300,918 million, absorbing the impact of the Accounting Standard for Revenue Recognition, etc. Gross profit decreased 1.8% year on year to ¥113,541 million. Operating income rose 100.8% year on year to ¥43,354 million while ordinary income increased 97.1% year on year to ¥43,230 million. Net income attributable to owners of the parent rose 96.4% year on year to ¥20,769 million. All income items from operating income, which is not affected by the said accounting standards, onwards increased significantly.

Results by business segment were as follows.

[Takara Shuzo]

Amid the backdrop of the persisting trend of decrease in total consumption of alcoholic beverages due to the impact of the decline and aging of the population in Japan among other factors, consumption styles are undergoing change due to the COVID-19 crisis. In addition, there has been an unabated rise in prices of raw materials due to the soaring prices of resources as well as the depreciation of the yen.

In this situation, Takara Shuzo gave the highest priority to supplying safe and secure products as a food manufacturer, while giving attention to the prevention of infection and spread of COVID-19. At the same time, Takara Shuzo has been committed to nurturing high value-added products that meet consumer needs, such as SDGs-conscious products, and to thorough cost reductions. However, in light of the large-scale voluntary recall of chu-hi products in May 2021, we are once again implementing thorough quality control.

The segment's sales and other information are as shown below.

Descriptions of sales by category are based on amounts before the application of the Accounting Standard for Revenue Recognition, etc.; however, the amounts shown in these segment results are after the application of the standard, and no comparisons with the previous year are shown, except for operating income.

In shochu, overall sales declined slightly due to a decrease in sales of honkaku shochu, which was affected by the voluntary restriction of business activities by eating and drinking establishments. In sake, although sales for export increased with the recovery of overseas markets, overall sales decreased due to the impact of the voluntary restriction of business activities by eating and drinking establishments. In light-alcohol refresher, although sales of *Takara Shochu Highball* continued to increase, sales of lemon sours declined due to the impact of a voluntary recall of products. Consequently, sales of light-alcohol refreshers as a whole decreased slightly. In seasonings, overall sales rose due to the increase in sales of Hon-Mirin, cooking sake and other seasonings. In raw alcohol, etc., net sales declined.

As a result, net sales for the Takara Shuzo Group totaled ¥119,710 million, affected by the impact of a ¥29,000 million decrease due to application of the Accounting Standard for Revenue Recognition, etc. Cost of sales was ¥90,898 million, while gross profit was ¥28,811 million. As SG&A expenses were ¥24,676, also affected by the ¥29,000 million decrease, operating income decreased 15.2% year on year to ¥4,135 million.

[Takara Shuzo International Group]
The Takara Shuzo International Group engages in the Overseas Alcoholic Beverages Business, which entails exports from Japan and the manufacture and sale of alcoholic beverages in overseas locations, and the Japanese Food Wholesale Business in overseas markets, through which it sells Japanese food ingredients to Japanese food restaurants and retailers outside Japan. The impact of COVID-19, which was a factor in the decline in sales in the previous fiscal year, has gradually eased, due to the expansion of vaccines and other factors, although there are regional differences.

The segment's sales and other information are as follows:

Overseas Alcoholic Beverages Business
Sales of Blanton's, the premium single-barrel bourbon, remained brisk, while those of Tomatin Scotch whisky also grew. Sales of sake and other Japanese alcoholic beverages recovered from the previous fiscal year, when they were greatly affected by the COVID-19 crisis, and export from Japan also increased. As a result, net sales of the Overseas Alcoholic Beverages Business rose 39.2% year on year to ¥14,063 million.

Japanese Food Wholesale Business in overseas markets
Amid the COVID-19 crisis, the Japanese Food Wholesale Business in overseas markets engaged in efforts to bolster sales to retailers and also to expand online sales, and there was a sharp recovery in sales following the reopening of restaurant operations in major cities, leading to a net sales increase of 48.5% year on year to ¥89,728 million.

As a result, net sales for the Takara Shuzo International Group after the elimination of intersegment transactions rose 46.8% year on year to ¥102,186 million, bolstered by the effect of the weak yen. Cost of sales increased 43.0% year on year to ¥70,045 million, and gross profit rose 56.0 % year on year to ¥32,140 million. SG&A expenses rose only 21.0% year on year to ¥23,667 million despite increases in personnel expenses and logistics expenses due to higher sales. Accordingly, the Takara Shuzo International Group saw operating income significantly increase 712.1% year on year to ¥8,472 million.

[Takara Bio Group]
The Takara Bio Group has promoted initiatives aimed at becoming a drug discovery company that continually creates new modalities by going ahead with the development of platform technology for biologics discovery through its core businesses of reagents/instruments and CDMO services. It proactively worked on stable supply of polymerase chain reaction (PCR)-related products for COVID-19, improvement of the manufacturing structure of products such as regenerative medical products, including vaccines, and other initiatives.

As the Takara Bio Group's core business, the Bioindustry business mainly provides products and services that support research and development activities in biotechnology-related fields as such activities become increasingly widespread. Furthermore, in the Gene Therapy business, with advances in biology and technology, there has been a rapid expansion in the field of medicine to develop new modalities (therapeutic means) such as genes and cells, in addition to small molecules and antibodies. Under these circumstances, the Takara Bio Group is working to maximize project value through the development of platform technology for biologics discovery necessary for the development of gene therapy and other regenerative medicine products and vaccines, the creation of new clinical projects, and the licensing of development projects to pharmaceutical companies.

Sales of reagents and CDMO increased year on year, despite a year-on-year decrease in sales of instruments and gene therapy. In particular, sales of reagents for general research use reached a record high due to the recovery from the COVID-19 crisis, and sales of polymerase chain reaction (PCR)-related reagents for COVID-19 also grew substantially.

As a result, net sales for the Takara Bio Group were up 46.9%year on year to ¥67,699 million. Cost of sales grew 30.1% year on year to ¥18,488 million due to improvement in the cost rate, leading to a gross

profit increase of 54.4% year on year to ¥49,211 million. SG&A expenses were up 13.3% year on year to ¥20,309 million due to increases in personnel expenses, research and development expenses and other expenses, and operating income was up 107.1% year on year to ¥28,902 million.

[Other]

The Other segment includes the real estate rental business, the transportation business, and the wine import and sale business. Net sales of the Other segment increased 5.1% year on year to ¥30,719 million. Cost of sales rose 4.2% year on year to ¥26,626 million, and gross profit increased 11.2% year on year to ¥4,093 million. SG&A expenses fell 0.3% year on year to ¥1,870 million, and operating income was up 23.2% year on year to ¥2,222 million.

Breakdown of sales results by product category

Segment / Product category	Previous Fiscal Year (From April 1, 2020 to March 31, 2021) Amount (Millions of yen)	Fiscal Year under Review (From April 1, 2021 to March 31, 2022) Amount (Millions of yen)	YoY Comparison (%)
Takara Shuzo			
Shochu	48,631	37,935	(22.0)
Sake	17,706	12,803	(27.7)
Light-alcohol refreshers	47,154	37,677	(20.1)
Other alcoholic beverages	5,573	5,467	(1.9)
Hon Mirin	13,367	9,097	(31.9)
Other seasonings	10,441	8,560	(18.0)
Raw alcohol, etc.	9,663	8,168	(15.5)
Total	152,537	119,710	(21.5)
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	10,100	14,063	39.2
Japanese Food Wholesales Business in overseas markets	60,431	89,728	48.5
Other	57	62	8.9
Elimination of intra-Group transaction on consolidation	(999)	(1,668)	—
Total	69,589	102,186	46.8
Takara Bio Group			
Reagents	35,189	54,605	55.2
Instruments	1,726	1,518	(12.1)
CDMO	8,901	11,426	28.4
Gene therapy	268	148	(44.5)
Total	46,086	67,699	46.9
Reported segment total	268,213	289,596	8.0
Other	29,238	30,719	5.1
Segment total	297,451	320,315	7.7
Sales not allocated to business segments and intersegment transactions	(19,007)	(19,396)	—
Total	278,443	300,918	8.1

Notes: 1. Amounts include alcohol tax.

2. From the beginning of the fiscal year under review, ended March 31, 2022, the names of the product categories of Takara Bio Group have been changed from “Research reagents,” “Scientific instruments” and “Contract services” to “Reagents,” “Instruments” and “CDMO.”

(Reference) [Before applying the Accounting Standard for Revenue Recognition]
Breakdown of sales results by product category

Segment	Previous Fiscal Year (From April 1, 2020 to March 31, 2021)	Fiscal Year under Review (From April 1, 2021 to March 31, 2022)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	48,631	47,521	(2.3)
Sake	17,706	16,160	(8.7)
Light-alcohol refreshers	47,154	46,439	(1.5)
Other alcoholic beverages	5,573	6,123	9.9
Hon Mirin	13,367	13,571	1.5
Other seasonings	10,441	10,712	2.6
Raw alcohol, etc.	9,663	8,181	(15.3)
Total	152,537	148,710	(2.5)
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	10,100	14,092	39.5
Japanese Food Wholesales Business in overseas markets	60,431	89,728	48.5
Other	57	62	8.9
Elimination of intra-Group transaction on consolidation	(999)	(1,668)	—
Total	69,589	102,214	46.9
Takara Bio Group			
Reagents	35,189	54,605	55.2
Instruments	1,726	1,518	(12.1)
CDMO	8,901	11,426	28.4
Gene therapy	268	148	(44.5)
Total	46,086	67,699	46.9
Reported segment total	268,213	318,625	18.8
Other	29,238	30,719	5.1
Segment total	297,451	349,344	17.4
Sales not allocated to business segments and intersegment transactions	(19,007)	(19,396)	—
Total	278,443	329,947	18.5

Note: For convenience of comparison, net sales for the fiscal year under review are the amounts to which the Accounting Standard for Revenue Recognition, etc. are not applied.

(2) Overview of Financial Position for the Fiscal Year under Review

(Assets)

At the end of the fiscal year under review, current assets totaled ¥232,323 million, an increase of ¥49,215 million compared with that at the end of the previous fiscal year. This was primarily due to increases in merchandise and finished goods of ¥22,056 million, cash and deposits of ¥14,207 million, and notes and accounts receivable-trade of ¥7,781 million.

Noncurrent assets were ¥130,114 million, an increase of ¥6,304 million compared with that at the end of the previous fiscal year. This was primarily due to an increase of ¥5,006 million in property, plant and equipment resulting from interior finishing work of Takara Bio USA, Inc.'s new office building, and Takara Bio Inc.'s acquisition of manufacturing facilities.

As a result, total assets were ¥362,438 million, an increase of ¥55,519 million compared with that at the end of the previous fiscal year.

(Liabilities)

At the end of the fiscal year under review, current liabilities totaled ¥79,151 million, an increase of ¥22,882 million compared with that at the end of the previous fiscal year. This was primarily due to increases in current portion of bonds of ¥10,000 million and other under current liabilities of ¥7,687 million.

Noncurrent liabilities were ¥58,730 million, a decrease of ¥383 million compared with that at the end of the previous fiscal year.

As a result, total liabilities were ¥137,882 million, an increase of ¥22,499 million compared with that at the end of the previous fiscal year.

(Net Assets)

At the end of the fiscal year under review, total net assets were ¥224,555 million, an increase of ¥33,020 million compared with that at the end of the previous fiscal year. This was primarily due to increases in retained earnings of ¥14,749 million, noncontrolling interests of ¥9,484 million, and foreign currency translation adjustment of ¥7,171 million.

As a result, the equity ratio totaled 49.8%, compared with 51.1% at the end of the previous fiscal year.

(3) Overview of Cash Flows for the Fiscal Year under Review

Net cash provided by operating activities decreased ¥10,724 million year on year to ¥16,376 million primarily due to income before income taxes of ¥40,961 million, depreciation and amortization of ¥8,425 million, an increase in notes and accounts receivable-trade of ¥7,109 million, an increase in inventories of ¥21,235 million, an increase in notes and accounts payable-trade of ¥3,920 million, and income taxes paid of ¥10,253 million.

Net cash used in investing activities resulted in expenditure of ¥10,399 million, an increase in expenditure of ¥3,660 million compared with that of the previous fiscal year primarily due to payments into time deposits of ¥15,513 million, proceeds from withdrawal of time deposits of ¥14,758 million, purchase of property, plant and equipment and intangible assets of ¥14,762 million, and subsidies received of ¥3,960 million.

Net cash provided by financing activities totaled ¥4,133 million (an expenditure of ¥1,506 million in the previous fiscal year) primarily due to proceeds from issuance of bonds of ¥9,927 million and cash dividends paid of ¥4,147 million.

As a result, cash and cash equivalents at fiscal year-end, including effect of exchange rate change on cash and cash equivalents, stood at ¥75,729 million, up ¥12,869 million from the previous fiscal year-end.

(4) Future Outlook

Takara Shuzo International Group expects to increase profits in both the Overseas Alcoholic Beverages Business and Japanese Food Wholesale Business in overseas markets by further cultivating the eating and drinking establishment channel and developing sales channels such as retailers, against the backdrop of the spread of Japanese food overseas. Despite the impact of higher costs, Takara Shuzo also expects to see an increase in profit due to expanded sales of high value-added products, price revisions, and other measures, as well as thorough cost reductions.

On the other hand, the Takara Bio Group expects a decrease in profits due to lower demand for PCR-

related reagents for COVID-19 and its plans to increase personnel expenses, R&D expenses, and other expenses.

As a result, regards the outlook for results for the following fiscal year, the year ending March 31, 2023, the Group is forecasting net sales of ¥301,000 million, operating income of ¥30,000 million, ordinary income of ¥30,400 million, and net income attributable to owners of the parent of ¥16,000 million. The details of the consolidated results forecasts and the results forecasts for each segment are described on pages 13/18-16/18 in "Supplement for the Consolidated Financial Statements."

2. Basic Concept on Selection of Accounting Standards

The Takara Group has a policy to prepare the Consolidated Financial Statements in accordance with the Japanese GAAP for the time being, taking into consideration comparability of the Consolidated Financial Statements across periods and companies.

As regards the application of the International Financial Reporting Standards, the Takara Group will take appropriate actions, taking into account the situations in Japan and other countries.

3. Consolidated Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2021	As of Mar. 31, 2022
Assets		
Current assets		
Cash and deposits	66,238	80,445
Notes and accounts receivable-trade	55,074	62,856
Electronically recorded monetary claims-operating	6,880	7,403
Securities	1,145	1,179
Merchandise and finished goods	41,115	63,172
Work in process	1,924	2,012
Raw materials and supplies	6,084	7,458
Other	5,161	8,243
Allowance for doubtful accounts	(516)	(449)
Total current assets	183,108	232,323
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	61,363	69,584
Accumulated depreciation	(35,403)	(36,902)
Buildings and structures, net	25,959	32,682
Machinery, equipment and vehicles	86,657	88,453
Accumulated depreciation	(71,247)	(73,447)
Machinery, equipment and vehicles, net	15,410	15,006
Land	20,640	20,170
Lease assets	1,680	1,512
Accumulated depreciation	(651)	(605)
Lease assets, net	1,029	907
Construction in progress	4,027	1,782
Other	21,823	24,046
Accumulated depreciation	(14,149)	(14,848)
Other, net	7,673	9,198
Total property, plant and equipment	74,740	79,747
Intangible assets		
Goodwill	10,142	10,070
Other	5,746	5,290
Total intangible assets	15,889	15,360
Investments and other assets		
Investment securities	27,924	29,228
Net defined benefit asset	894	907
Deferred tax assets	2,088	2,682
Other	2,341	2,253
Allowance for doubtful accounts	(69)	(64)
Total investments and other assets	33,180	35,006
Total noncurrent assets	123,810	130,114
Total assets	306,918	362,438

(Millions of Yen)

	As of Mar. 31, 2021	As of Mar. 31, 2022
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,481	20,973
Short-term loans payable	5,166	5,497
Current portion of bonds	—	10,000
Accrued alcohol tax	6,890	7,172
Accrued expenses	6,455	5,579
Income taxes payable	4,021	6,602
Provision for bonuses	2,727	3,161
Provision for sales promotion expenses	2,049	—
Other	12,476	20,164
Total current liabilities	56,269	79,151
Noncurrent liabilities		
Bonds payable	20,000	20,000
Long-term loans payable	15,465	15,248
Lease obligations	3,122	3,005
Deferred tax liabilities	3,831	3,969
Net defined benefit liability	9,274	8,944
Other	7,419	7,562
Total noncurrent liabilities	59,113	58,730
Total liabilities	115,383	137,882
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,292	2,499
Retained earnings	135,184	149,933
Treasury stock	(1,682)	(1,682)
Total shareholders' equity	149,020	163,976
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	11,370	12,216
Deferred gains or losses on hedges	193	412
Foreign currency translation adjustment	(2,840)	4,330
Remeasurements of defined benefit plans	(859)	(515)
Total accumulated other comprehensive income	7,863	16,443
Noncontrolling interests	34,650	44,135
Total net assets	191,535	224,555
Total liabilities and net assets	306,918	362,438

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(Millions of Yen)

	FY2021 (Apr. 1, 2020 – Mar. 31, 2021)	FY2022 (Apr. 1, 2021 – Mar. 31, 2022)
Net sales	278,443	300,918
Cost of sales	162,849	187,376
Gross profit	115,594	113,541
Selling, general and administrative expenses	93,999	70,187
Operating income	21,595	43,354
Nonoperating income		
Interest income	179	176
Dividends income	528	590
Rental income from real estate	137	157
Other	466	568
Total nonoperating income	1,311	1,492
Nonoperating expenses		
Interest expenses	344	330
Foreign exchange losses	92	807
Other	539	477
Total nonoperating expenses	976	1,615
Ordinary income	21,929	43,230
Extraordinary income		
National subsidies	517	4,470
Other	11	188
Total extraordinary income	529	4,658
Extraordinary loss		
Loss on tax purpose reduction entry of non-current assets	517	4,470
Loss on voluntary product recall	—	1,190
Loss on liquidation of business	458	—
Other	899	1,267
Total extraordinary losses	1,875	6,928
Income before income taxes	20,583	40,961
Income taxes-current	6,303	11,900
Income taxes-deferred	23	(309)
Total income taxes	6,326	11,590
Net income	14,256	29,370
Net income attributable to the noncontrolling interest	3,682	8,601
Net income attributable to owners of the parent	10,574	20,769

(Consolidated Statements of Comprehensive Income)

(Millions of Yen)

	FY2021 (Apr. 1, 2020 – Mar. 31, 2021)	FY2022 (Apr. 1, 2021– Mar. 31, 2022)
Net income	14,256	29,370
Other comprehensive income		
Valuation difference on available-for-sale securities	4,245	845
Deferred gains or losses on hedges	108	219
Foreign currency translation adjustment	(2,342)	9,189
Remeasurements of defined benefit plans	51	367
Total other comprehensive income	2,063	10,622
Comprehensive income	16,320	39,992
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	13,238	29,349
Comprehensive income attributable to noncontrolling interest	3,081	10,643

(3) Consolidated Statements of Change in Net Assets

FY2021 (Apr. 1, 2020 – Mar. 31, 2021)

(Millions of Yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance at the beginning of current period	13,226	2,454	128,564	(1,682)	142,563
Changes of items during the period					
Dividends from surplus			(3,954)		(3,954)
Net income			10,574		10,574
Purchase of treasury stock				(0)	(0)
Disposal of treasury stock		(0)		0	0
Purchase of shares of consolidated subsidiaries		(161)			(161)
Transfer to capital surplus from retained earnings		0	(0)		–
Net changes of items other than shareholders' equity					
Total changes of items during the period	–	(161)	6,619	(0)	6,457
Balance at the end of current period	13,226	2,292	135,184	(1,682)	149,020

	Accumulated other comprehensive income					Noncontrolling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	7,125	84	(1,102)	(908)	5,199	33,566	181,329
Changes of items during the period							
Dividends from surplus							(3,954)
Net income							10,574
Purchase of treasury stock							(0)
Disposal of treasury stock							0
Purchase of shares of consolidated subsidiaries							(161)
Transfer to capital surplus from retained earnings							–
Net changes of items other than shareholders' equity	4,245	108	(1,738)	48	2,664	1,083	3,748
Total changes of items during the period	4,245	108	(1,738)	48	2,664	1,083	10,206
Balance at the end of current period	11,370	193	(2,840)	(859)	7,863	34,650	191,535

FY2022 (Apr. 1, 2021 – Mar. 31, 2022)

(Millions of Yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance at the beginning of current period	13,226	2,292	135,184	(1,682)	149,020
Cumulative effects of changes in accounting policies			(1,867)		(1,867)
Restated balance	13,226	2,292	133,316	(1,682)	147,152
Changes of items during the period					
Dividends from surplus			(4,151)		(4,151)
Net income			20,769		20,769
Purchase of treasury stock				(0)	(0)
Disposal of treasury stock		0		0	0
Purchase of shares of consolidated subsidiaries		206			206
Net changes of items other than shareholders' equity					
Total changes of items during the period	—	206	16,617	(0)	16,823
Balance at the end of current period	13,226	2,499	149,933	(1,682)	163,976

	Accumulated other comprehensive income					Noncontrolling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	11,370	193	(2,840)	(859)	7,863	34,650	191,535
Cumulative effects of changes in accounting policies							(1,867)
Restated balance	11,370	193	(2,840)	(859)	7,863	34,650	189,667
Changes of items during the period							
Dividends from surplus							(4,151)
Net income							20,769
Purchase of treasury stock							(0)
Disposal of treasury stock							0
Purchase of shares of consolidated subsidiaries							206
Net changes of items other than shareholders' equity	845	219	7,171	343	8,580	9,484	18,064
Total changes of items during the period	845	219	7,171	343	8,580	9,484	34,888
Balance at the end of current period	12,216	412	4,330	(515)	16,443	44,135	224,555

(4) Consolidated Statements of Cash Flows

(Millions of Yen)

	FY2021 (Apr. 1, 2020 – Mar. 31, 2021)	FY2022 (Apr. 1, 2021– Mar. 31, 2022)
Net cash provided by (used in) operating activities		
Income before income taxes	20,583	40,961
Depreciation and amortization	8,068	8,425
Impairment loss	432	185
Loss on liquidation of business	458	—
Amortization of goodwill	865	875
Increase (decrease) in provision for sales promotion expenses	(44)	(2,049)
Interest and dividends income	(707)	(767)
Interest expenses	344	330
Loss (gain) on sales and retirement of non-current assets	291	319
Decrease (increase) in notes and accounts receivable-trade	(1,162)	(7,109)
Decrease (increase) in inventories	(691)	(21,235)
Increase (decrease) in notes and accounts payable-trade	40	3,920
Increase (decrease) in liquor taxes payable	(799)	281
Increase (decrease) in accrued consumption taxes	1,722	(1,890)
Increase (decrease) in other current liabilities	2,442	3,372
Other, net	(496)	(112)
Subtotal	31,347	25,506
Interest and dividends income received	703	787
Interest expenses paid	(364)	(334)
Income taxes paid	(4,767)	(10,253)
Subsidies received	181	671
Net cash provided by (used in) operating activities	27,100	16,376
Net cash provided by (used in) investing activities		
Payments into time deposits	(4,316)	(15,513)
Proceeds from withdrawal of time deposits	5,407	14,758
Proceeds from sales and redemption of securities	4,455	—
Purchase of property, plant and equipment and intangible assets	(13,911)	(14,762)
Proceeds from sale of property, plant and equipment and intangible assets	28	1,326
Subsidies received	1,900	3,960
Other, net	(302)	(169)
Net cash provided by (used in) investing activities	(6,738)	(10,399)
Net cash provided by (used in) financing activities		
Proceeds from long-term borrowings	10,068	5
Proceeds from issuance of bonds	—	9,927
Redemption of bonds	(5,000)	—
Proceeds from issuance of commercial papers	5,000	—
Redemption of commercial papers	(5,000)	—
Cash dividends paid	(3,951)	(4,147)
Dividends paid to noncontrolling interests	(397)	(763)
Repayments of lease obligations	(689)	(710)
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	(1,761)	(175)
Other, net	224	(2)
Net cash provided by (used in) financing activities	(1,506)	4,133
Effect of exchange rate change on cash and cash equivalents	(536)	2,758
Net increase (decrease) in cash and cash equivalents	18,319	12,869
Cash and cash equivalents at beginning of period	44,541	62,860
Cash and cash equivalents at end of period	62,860	75,729

(5) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Changes in Accounting Policies)

(Application of Accounting Standard for Revenue Recognition, etc.)

The Company adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29, March 31, 2020, hereinafter referred to as the "Accounting Standard for Revenue Recognition"), etc. from the beginning of the fiscal year under review and recognized revenue when control of promised goods or services is transferred to customers in an amount that is expected to be received in exchange for those goods or services. As a result, part of consideration paid to customers, which was previously treated as SG&A expenses, is deducted from net sales. In addition, an amount that is expected to be paid to customers after the balance sheet date, which was previously presented as part of "accrued expenses" and as "provision for sales promotion expenses" under "current liabilities," is included in "other" under "current liabilities" as refund liabilities.

With regard to the application of the Accounting Standard for Revenue Recognition, etc., in accordance with the transitional treatment stipulated in the provisions of Paragraph 84 of the Accounting Standard for Revenue Recognition, the cumulative effect of retrospectively applying the new accounting policy prior to the beginning of the fiscal year under review was added to or deducted from retained earnings at the beginning of the fiscal year under review, and a new accounting policy was applied from the beginning balance of the fiscal year under review.

As a result, in the fiscal year under review, net sales and SG&A expenses each decreased by ¥29,028 million. There was no impact on operating income, ordinary income, or income before income taxes. In addition, retained earnings at the beginning of the fiscal year under review decreased by ¥1,867 million, and refund liabilities included in "other" under current liabilities as of March 31, 2022 were ¥6,328 million.

The impact on per share information is described in "3. Consolidated Financial Statements and Primary Notes (5) Notes to Consolidated Financial Statements (Per Share Information).

(Application of Accounting Standard for Fair Value Measurement)

The Company adopted the "Accounting Standard for Fair Value Measurement" (ASBJ Statement No. 30, July 4, 2019, hereinafter referred to as the "Accounting Standard for Fair Value Measurement"), etc. from the beginning of the fiscal year under review, and decided to apply new accounting policies prescribed in the Accounting Standard for Fair Value Measurement in the future, in accordance with the transitional treatment as stipulated in Paragraph 19 of the Accounting Standard for Fair Value Measurement and Paragraph 44-2 of the "Accounting Standards for Financial Instruments" (ASBJ Statement No. 10, July 4, 2019).

(Segment Information)

1. Overview of Reported Segments

Reporting segments are the segments of the Takara Group for which financial information can be obtained. The Board of Directors, the top organization for decision making on Group management, examines such information to determine the allocation of management resources and evaluate the business performance on a regular basis.

The Group consists of the corporate groups centered on the operating companies Takara Shuzo Co., Ltd., Takara Shuzo International Co., Ltd. and Takara Bio Inc.; other businesses; and the Company, which manages the whole group as the holding company. All operating companies develop comprehensive business strategies, covering both domestic and overseas operations, for the goods, products and services that they offer, and work to expand their business operations. Accordingly, the Group has defined three reported segments based on the content of goods, products and services, while taking into consideration the scope of managerial responsibility and the capacity to evaluate business performance. These three reported segments are Takara Shuzo, the Takara Shuzo International Group, and the Takara Bio Group.

Takara Shuzo primarily engages in the manufacture and sale of alcoholic beverages and seasonings in Japan. The Takara Shuzo International Group engages in the export of alcoholic beverages from Japan, the manufacture and sale of alcoholic beverages at overseas locations, and the Japanese Food Wholesale Business in overseas markets. The Takara Bio Group engages in

development of basic technologies for bio drug discovery through the business of reagents and instruments as well as CDMO services.

2. Calculation method for net sales, income or loss, assets, and other items of each reported segment

The accounting treatment of reported business segments is generally the same as that explained in "Basis of Presentation of Consolidated Financial Statements."

The figures for the income of reported segments are based on operating income. Intersegment income is based on the prevailing market price.

As described in "Changes in Accounting Policies," the Company adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29, March 31, 2020), etc. from the beginning of the fiscal year under review, and changed the accounting method for revenue recognition. Accordingly, the measurement method of income or loss by business segment has also been changed.

As a result of these changes, compared with the amounts calculated by the conventional accounting method, net sales of Takara Shuzo decreased by ¥29,000 million in the fiscal year under review, while net sales of the Takara Shuzo International Group decreased by ¥28 million.

3. Net sales, Income (Loss), Assets and Other items by Reported Segment

Previous Fiscal Year (From April 1, 2020, to March 31, 2021)

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	151,972	69,348	46,086	267,407	11,036	278,443	0	278,443
Intersegment	564	240	0	805	18,202	19,007	(19,007)	—
Total	152,537	69,589	46,086	268,213	29,238	297,451	(19,007)	278,443
Segment income (loss)	4,879	1,043	13,952	19,875	1,803	21,679	(84)	21,595
Segment assets	90,221	74,373	89,750	254,344	19,932	274,277	32,641	306,918
Other items								
Depreciation and amortization	2,848	1,430	3,220	7,498	233	7,732	336	8,068
Amortization of goodwill	—	379	486	865	—	865	—	865
Investment in equity-method affiliates	—	—	—	—	—	—	1,727	1,727
Increase in total fixed assets, property, plant and equipment and intangible assets	1,430	2,802	8,897	13,130	334	13,464	310	13,775

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2 Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income (loss) comprises intersegment eliminations of ¥69 million and loss of the Company not allocated to business segments of ¥(153) million.

(3) Segment assets include assets of the Company not allocated to business segments of ¥62,585 million and other adjustment (principally intersegment eliminations) of ¥(29,944) million. Assets attributed to the Company include surplus funds and long-term investment assets.

(4) Depreciation and amortization primarily comprises depreciation and amortization recognized by the Company.

(5) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.

(6) Increase in total fixed assets, property, plant and equipment and intangible assets is the increase recorded by the Company.

3. Segment income (loss) has been adjusted to the operating income of consolidated financial statements.

Fiscal Year under Review (From April 1, 2021, to March 31, 2022)

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	118,889	101,920	67,699	288,510	12,408	300,918	—	300,918
Intersegment	820	265	0	1,086	18,310	19,396	(19,396)	—
Total	119,710	102,186	67,699	289,596	30,719	320,315	(19,396)	300,918
Segment income (loss)	4,135	8,472	28,902	41,510	2,222	43,733	(379)	43,354
Segment assets	90,442	89,836	115,712	295,991	19,836	315,827	46,610	362,438
Other items								
Depreciation and amortization	2,590	1,675	3,554	7,820	238	8,059	366	8,425
Amortization of goodwill	—	374	500	875	—	875	—	875
Investment in equity-method affiliates	—	—	—	—	—	—	1,769	1,769
Increase in total fixed assets, property, plant and equipment and intangible assets	1,785	844	13,180	15,810	208	16,018	194	16,213

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business of domestic Group companies among others.

2 Details of adjustment amounts are as follows.

(1) Segment income (loss) comprises intersegment eliminations of ¥34 million and loss of the Company not allocated to business segments of ¥(413) million.

(2) Segment assets include assets of the Company not allocated to business segments of ¥75,059 million and other adjustment (principally intersegment eliminations) of ¥(28,449) million. Assets attributed to the Company include surplus funds and long-term investment assets.

(3) Depreciation and amortization primarily comprises depreciation and amortization recognized by the Company.

(4) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.

(5) Increase in total fixed assets, property, plant and equipment and intangible assets is the increase recorded by the Company.

3. Segment income (loss) has been adjusted to the operating income of consolidated financial statements.

(Revenue Recognition)

Information on breakdown of revenue from contracts with customers

Period under Review (From April 1, 2021, to March 31, 2022)

(Millions of yen)

	Reported Segment				Other (Note)	Total
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal		
Alcoholic Beverages Business	118,889	12,194	—	131,084	4,542	135,626
Japanese Food Wholesales Business in overseas markets	—	89,725	—	89,725	—	89,725
Bio	—	—	67,699	67,699	—	67,699
Other	—	—	—	—	7,261	7,261
Revenue earned from contracts with customers	118,889	101,920	67,699	288,510	11,803	300,313
Other revenue	—	—	—	—	605	605
Net sales to external customers	118,889	101,920	67,699	288,510	12,408	300,918

Note: Other includes business segments that are not part of reported segments, revenue from the import and sale of wine and from freight delivery services is included in “Revenue earned from contracts with customers,” and revenue from real estate rental is included in “Other revenue” based on ASBJ Statement No. 13 “Accounting Standard for Lease Transactions.”

(Per Share Information)

	Previous Fiscal Year (From April 1, 2020, to March 31, 2021)	Fiscal Year under Review (From April 1, 2021, to March 31, 2022)
Net assets per share	¥793.53	¥912.58
Profit per share	¥53.48	¥105.05

Notes 1. Fully diluted profit per share is not presented since there were no potential shares.

2. The basis of calculation of net assets per share is as follows.

	Previous Fiscal Year (As of March 31, 2021)	Fiscal Year under Review (As of March 31, 2022)
Total net assets (¥ million)	191,535	224,555
Amount deducted from total net assets (¥ million)	34,650	44,135
(of which minority interests) (¥ million)	(34,650)	(44,135)
Net assets at term-end related to shares of common stock (¥ million)	156,884	180,420
Shares of common stock at term-end used to calculate net assets per share (1,000 shares)	197,704	197,704

3. The basis of calculation of net income per share and fully diluted net income per share is as follows.

	Previous Fiscal Year (From April 1, 2020, to March 31, 2021)	Fiscal Year under Review (From April 1, 2021, to March 31, 2022)
Net income attributable to owners of the parent (¥ million)	10,574	20,769
Amount not belonging to common shareholders (¥ million)	―	―
Net income related to shares of common stock (¥ million)	10,574	20,769
Average number of shares outstanding during the term (1,000 shares)	197,704	197,704

4. As described in “Changes in Accounting Policies,” the Company adopted the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020), etc., and followed the transitional treatment stipulated in the proviso to Paragraph 84 of the Accounting Standard for Revenue Recognition. As a result, net assets per share for the fiscal year under review decreased by ¥9.45. There is no impact on profit per share.

(Significant Subsequent Events)

No items to report.

2022年3月期
決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Year Ended March 31, 2022

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
① グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)
② 要約貸借対照表
Consolidated Balance Sheets (Summary)
2. 宝酒造
Takara Shuzo
要約損益計算書
Statements of Income (Summary)
3. 宝酒造インターナショナルグループ
Takara Shuzo International Group
要約損益計算書
Statements of Income (Summary)
4. タカラバイオグループ
Takara Bio Group
要約損益計算書
Statements of Income (Summary)
5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group
6. 2022年3月期　参考資料
Reference Data for the Year Ended March 31, 2022
7. 2022年3月期業績【「収益認識に関する会計基準」等適用前】
Results for the year ended March 31, 2022 based on before the application of
【Accounting Standard for Revenue Recognition】
8. 2023年3月期 業績予想
Financial forecast for the year ending March 31, 2023
① 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
② 宝酒造
Takara Shuzo
③ 宝酒造インターナショナルグループ
Takara Shuzo International Group
④ タカラバイオグループ
Takara Bio Group
9. 2023年3月期　参考資料
Reference Data for the year ending March 31, 2023

宝ホールディングス株式会社
TAKARA HOLDINGS INC.
財務・IR部　Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	2021年3月期 FY2021	2022年3月期 FY2022/ Apr. 1, 2021 - Mar. 31, 2022		対前期 Change from FY2021		対2/10予想 Change from forecast anounced Feb. 2022	
	実績 Actual (a)	2/10予想 Forecast announced Feb. 10, 2022 (b)	実績 Actual (c)	増減 Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減 Difference (c-b)	率(c/b-1) YOY% (c/b-1)
宝酒造 Takara Shuzo	152,537	119,552	119,710	△ 32,827	△21.5%	158	0.1%
宝酒造インターナショナルグループ Takara Shuzo International Group	69,589	102,168	102,186	32,596	46.8%	18	0.0%
タカラバイオ グループ Takara Bio Group	46,086	65,000	67,699	21,613	46.9%	2,699	4.2%
その他 Other	29,238	30,260	30,719	1,481	5.1%	459	1.5%
調整額 Adjustment	△ 19,007	△ 18,980	△ 19,396	△ 389	—	△ 416	—
売上高 Net sales	278,443	298,000	300,918	22,474	8.1%	2,918	1.0%
売上原価 Cost of sales	162,849	187,100	187,376	24,527	15.1%	276	0.1%
売上総利益 Gross profit	115,594	110,900	113,541	△ 2,052	△1.8%	2,641	2.4%
運送費、保管料 Transportation and storage	10,937	12,200	12,076	1,139	10.4%	△ 123	△1.0%
広告宣伝費 Advertising	2,251	2,500	2,510	259	11.5%	10	0.4%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	34,128	3,900	3,883	△ 30,245	△88.6%	△ 16	△0.4%
研究開発費 Research and development	5,914	6,500	6,484	570	9.6%	△ 15	△0.2%
管理費、その他 Other, net	40,768	45,400	45,232	4,464	11.0%	△ 167	△0.4%
販売費及び一般管理費 SG&A expenses	93,999	70,500	70,187	△ 23,811	△25.3%	△ 312	△0.4%
宝酒造 Takara Shuzo	4,879	4,200	4,135	△ 743	△15.2%	△ 64	△1.5%
宝酒造インターナショナルグループ Takara Shuzo International Group	1,043	8,470	8,472	7,429	712.1%	2	0.0%
タカラバイオ グループ Takara Bio Group	13,952	26,000	28,902	14,949	107.1%	2,902	11.2%
その他 Other	1,803	2,128	2,222	419	23.2%	94	4.5%
調整額 Adjustment	△ 84	△ 398	△ 379	△ 295	—	18	—
営業利益(△:損失) Operating income(Δ:loss)	21,595	40,400	43,354	21,759	100.8%	2,954	7.3%
受取利息・配当金 Interest and Dividends income	707	750	767	59	8.5%	17	2.3%
その他営業外収益 Other, net	603	550	725	121	20.1%	175	31.9%
営業外収益 Non-operating income	1,311	1,300	1,492	181	13.8%	192	14.8%
支払利息 Interest and discounts expenses	344	300	330	△ 13	△3.9%	30	10.3%
その他営業外費用 Other, net	632	400	1,284	652	103.3%	884	221.2%
営業外費用 Non-operating expenses	976	700	1,615	639	65.5%	915	130.8%
経常利益(△:損失) Ordinary income(Δ:loss)	21,929	41,000	43,230	21,300	97.1%	2,230	5.4%
特別利益 Extraordinary income	529	5,000	4,658	4,129	780.5%	△ 341	△6.8%
特別損失 Extraordinary loss	1,875	6,900	6,928	5,052	269.4%	28	0.4%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	20,583	39,100	40,961	20,377	99.0%	1,861	4.8%
法人税、住民税及び事業税 Current income taxes	6,303	11,200	11,900	5,596	88.8%	390	3.5%
法人税等調整額 Deferred income taxes	23		△ 309	△ 332	—		
当期純利益(△:損失) Net income(Δ:loss)	14,256	27,900	29,370	15,113	106.0%	1,470	5.3%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	3,682	8,300	8,601	4,918	133.6%	301	3.6%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	10,574	19,600	20,769	10,194	96.4%	1,169	6.0%
設備投資額(有形・無形) Capital expenditures	13,775	18,350	16,213	2,438	17.7%	△ 2,136	△11.6%
減価償却費(有形・無形) Depreciation and Amortization	8,068	8,400	8,425	356	4.4%	25	0.3%
のれん償却額 Amortization of goodwill	865	900	875	9	1.2%	△ 24	△2.7%

営業外収益 Non-operating income	受取利息 176、受取配当金 590 など Interest income 176, Dividends income 590, etc.
営業外費用 Non-operating expenses	支払利息 234、社債利息 96、為替差損 807 など Interest expense 234, Interest on bonds 96, Foreign exchange losses 807 etc.
特別利益 Extraordinary income	国庫補助金 4,470 など (前期:国庫補助金 517 など) National subsidies 4,470 etc.(FY2021:National subsidies 517 etc.)
特別損失 Extraordinary loss	固定資産圧縮損 4,470、製品自主回収関連 1,190 など Loss on tax purpose reduction entry of non-current assets 4,470, Loss on product recall 1,190, etc.

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets

（百万円 :Millions of Yen）

	2021年3月期 3月期末 As of Mar. 31, 2021	2022年3月期 3月期末 As of Mar. 31, 2022	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	183,108	232,323	49,215	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	66,238	80,445	14,207	TH +136.2
受取手形及び売掛金 Notes and accounts receivable-trade	61,954	70,260	8,305	TB +49.0
有価証券 Marketable securities	1,145	1,179	33	
棚卸資産 Inventories	49,124	72,643	23,518	うち 商品及び製品 TB +140.7 TS +10.4 Merchandise and finished goods
その他 Other current assets	5,161	8,243	3,082	
貸倒引当金 Allowance for doubtful accounts	△ 516	△ 449	67	
（固定資産） (Total fixed assets)	123,810	130,114	6,304	
〔有形固定資産〕 [Property, plant and equipment]	74,740	79,747	5,006	
建物及び構築物 Buildings and structures	25,959	32,682	6,722	（当期の有形・無形固定資産の主な増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	15,410	15,006	△ 404	新規取得 TS＋17.8、TSI＋8.2、TB＋129.6 Newly purchases
土地 Land	20,640	20,170	△ 469	減価償却 TS△25.7、TSI△14.9、TB△27.2 Depreciation
その他 Other property, plant and equipment	12,729	11,888	△ 841	圧縮損 TB△44.6 compression loss
〔無形固定資産〕 [Intangible fixed assets]	15,889	15,360	△ 528	
のれん Goodwill	10,142	10,070	△ 72	
その他 Other intangible fixed assets	5,746	5,290	△ 456	
〔投資その他の資産〕 [Investments and other assets]	33,180	35,006	1,826	
投資有価証券 Investment securities	27,924	29,228	1,303	うち 時価評価 TH +14.0 TS △1.8 Market valuation
その他 Other assets	5,324	5,843	518	
貸倒引当金 Allowance for doubtful accounts	△ 69	△ 64	4	
資産合計 Total assets	306,918	362,438	55,519	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets （百万円 :Millions of Yen）

	2021年3月期 3月期末 As of Mar. 31, 2021	2022年3月期 3月期末 As of Mar. 31, 2022	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	56,269	79,151	22,882	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	16,481	20,973	4,491	
短期借入金 Short-term loans payable	5,166	5,497	331	
1年内償還予定の社債 Current portion of bonds	―	10,000	10,000	TH +100.0(第13,14回普通社債 2022年4月償還) (#13,14SB Redemption Apr.2022)
未払酒税 Accrued alcohol tax	6,890	7,172	282	
未払費用 Accrued expenses	6,455	5,579	△ 875	
販売促進引当金 Reserve for sales promotion expenses	2,049	―	△ 2,049	
その他 Other current liabilities	19,226	29,928	10,702	
(固定負債) (Total non-current liabilities)	59,113	58,730	△ 383	
社債 Bonds payable	20,000	20,000	―	
長期借入金 Long-term loans payable	15,465	15,248	△ 217	
退職給付に係る負債 Net defined benefit liability	9,274	8,944	△ 329	
預り金 Deposits from customers	5,136	5,089	△ 46	
その他 Other non-current liabilities	9,236	9,447	210	
負債合計 Total liabilities	115,383	137,882	22,499	
資本金 Capital stock	13,226	13,226	―	
資本剰余金 Capital surplus	2,292	2,499	206	
利益剰余金 Retained earnings	135,184	149,933	14,749	
自己株式 Treasury stock	△ 1,682	△ 1,682	△ 0	
(株主資本) (Total owner's equity)	149,020	163,976	14,955	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	11,370	12,216	845	
繰延ヘッジ損益 Deffered gains or losses on hedges	193	412	219	
為替換算調整勘定 Translation adjustments	△ 2,840	4,330	7,171	TSI +48.9、TB +22.7 USD=115.02JPY, EUR=130.52JPY, GBP=155.24JPY (2021年12月) USD=103.52JPY, EUR=126.99JPY, GBP=139.87JPY (2020年12月)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 859	△ 515	343	
(その他の包括利益累計額) (Total valuation and translation adjustments)	7,863	16,443	8,580	
(非支配株主持分) (Noncontrolling interests)	34,650	44,135	9,484	
純資産合計 Total net assets	191,535	224,555	33,020	
負債純資産合計 Total liabilities and net assets	306,918	362,438	55,519	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

2. 宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2021年3月期 FY2021	2022年3月期 FY2022/ Apr. 1, 2021 - Mar. 31, 2022		対前期 Change from FY2021		対2/10予想 Change from forecast anounced Feb. 2022	
	実績 Actual (a)	2/10予想 Forecast announced Feb. 10, 2022 (b)	実績 Actual (c)	増減 Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減 Difference (c-b)	率(c/b-1) YOY% (c/b-1)
焼酎 Shochu	48,631	37,902	37,935	△ 10,695	△ 22.0%	33	0.1%
清酒 Sake	17,706	12,841	12,803	△ 4,902	△ 27.7%	△ 37	△ 0.3%
ソフトアルコール飲料 Light-alcohol refreshers	47,154	37,848	37,677	△ 9,477	△ 20.1%	△ 170	△ 0.5%
その他酒類 Other liquors	5,573	5,412	5,467	△ 106	△ 1.9%	55	1.0%
本みりん Hon Mirin	13,367	8,991	9,097	△ 4,270	△ 31.9%	106	1.2%
その他調味料 Other seasonings	10,441	8,470	8,560	△ 1,880	△ 18.0%	90	1.1%
原料用アルコール等 Raw alcohol	9,663	8,088	8,168	△ 1,494	△ 15.5%	80	1.0%
売上高 Net sales	152,537	119,552	119,710	△ 32,827	△ 21.5%	158	0.1%
売上原価 Cost of sales	92,439	90,633	90,898	△ 1,540	△ 1.7%	265	0.3%
売上総利益 Gross profit	60,098	28,919	28,811	△ 31,286	△ 52.1%	△ 107	△ 0.4%
運送費、保管料 Transportation and storage	8,173	8,147	8,134	△ 39	△ 0.5%	△ 12	△ 0.2%
広告宣伝費 Advertising	2,089	2,344	2,327	238	11.4%	△ 16	△ 0.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,981	2,432	2,423	△ 30,558	△ 92.7%	△ 8	△ 0.4%
研究開発費 Research and development	363	347	366	2	0.6%	19	5.5%
管理費、その他 Other, net	11,610	11,449	11,425	△ 185	△ 1.6%	△ 23	△ 0.2%
販売費及び一般管理費 SG&A expenses	55,218	24,719	24,676	△ 30,542	△ 55.3%	△ 42	△ 0.2%
営業利益（△：損失） Operating income(Δ:loss)	4,879	4,200	4,135	△ 743	△ 15.2%	△ 64	△ 1.5%
営業外収益 Non-operating income	239	259	281	42	17.5%	22	8.8%
営業外費用 Non-operating expenses	402	318	346	△ 55	△ 13.8%	28	9.1%
経常利益（△：損失） Ordinary income(Δ:loss)	4,716	4,141	4,070	△ 646	△ 13.7%	△ 70	△ 1.7%
特別利益 Extraordinary gain	0	111	110	110	53,775.9%	△ 0	△ 0.1%
特別損失 Extraordinary loss	188	1,689	1,321	1,133	600.4%	△ 367	△ 21.7%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	4,528	2,563	2,859	△ 1,668	△ 36.9%	296	11.6%
法人税、住民税及び事業税 Current income taxes	1,469	818	1,007	△ 461	△ 31.4%	△ 558	△ 38.0%
法人税等調整額 Deferred income taxes	△ 43		△ 96	△ 52	—		
当期純利益（△：損失） Net income(Δ:loss)	3,102	1,745	1,948	△ 1,154	△ 37.2%	203	11.7%
設備投資額（有形・無形） Capital expenditures	1,430	2,094	1,785	354	24.8%	△ 308	△ 14.7%
減価償却費（有形・無形） Depreciation and Amortization	2,848	2,601	2,590	△ 257	△ 9.1%	△ 10	△ 0.4%

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2021年3月期 FY2021	2022年3月期 FY2022/ Apr. 1, 2021 - Mar. 31, 2022		対前期 Change from FY2021		対2/10予想 Change from forecast anounced Feb. 2022	
	実績 Actual (a)	2/10予想 Forecast announced Feb. 10, 2022 (b)	実績 Actual (c)	増減 Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減 Difference (c-b)	率(c/b-1) YOY% (c/b-1)
海外酒類事業 Overseas Alcoholic beverages business	10,100	14,042	14,063	3,963	39.2%	21	0.2%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	60,431	89,826	89,728	29,297	48.5%	△ 97	△ 0.1%
その他 Other	57	57	62	5	8.9%	5	9.2%
連結消去 Elimination	△ 999	△ 1,757	△ 1,668	△ 669	—	88	—
売上高 Net sales	69,589	102,168	102,186	32,596	46.8%	18	0.0%
売上原価 Cost of sales	48,983	69,965	70,045	21,061	43.0%	80	0.1%
売上総利益 Gross profit	20,605	32,203	32,140	11,535	56.0%	△ 62	△ 0.2%
運送費、保管料 Transportation and storage	2,283	3,466	3,490	1,206	52.9%	24	0.7%
広告宣伝費 Advertising	91	115	112	20	22.6%	△ 2	△ 2.4%
販売促進費 Sales promotion	553	818	812	259	46.8%	△ 5	△ 0.7%
管理費、その他 Other, net	16,634	19,334	19,253	2,618	15.7%	△ 80	△ 0.4%
販売費及び一般管理費 SG&A expenses	19,562	23,733	23,667	4,105	21.0%	△ 65	△ 0.3%
海外酒類事業 Overseas Alcoholic beverages business	2,256	3,764	3,781	1,525	67.6%	17	0.5%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	286	6,158	6,112	5,825	2,032.1%	△ 45	△ 0.7%
その他 Other	△ 1,042	△ 969	△ 933	108	—	35	—
連結消去 Elimination	△ 457	△ 483	△ 487	△ 30	—	△ 4	—
営業利益（△：損失） Operating income(Δ:loss)	1,043	8,470	8,472	7,429	712.1%	2	0.0%
営業外収益 Non-operating income	180	298	297	117	65.3%	△ 0	△ 0.1%
営業外費用 Non-operating expenses	318	216	309	△ 8	△ 2.8%	93	43.3%
経常利益（△：損失） Ordinary income(Δ:loss)	904	8,552	8,461	7,556	834.9%	△ 90	△ 1.1%
特別利益 Extraordinary gain	3	3	3	△ 0	△ 17.7%	0	0.1%
特別損失 Extraordinary loss	477	205	202	△ 274	△ 57.6%	△ 2	△ 1.2%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	431	8,350	8,261	7,830	1,815.0%	△ 88	△ 1.1%
法人税、住民税及び事業税 Current income taxes	△ 7	2,055	2,159	2,166	—	54	2.7%
法人税等調整額 Deferred income taxes	35		△ 49	△ 84	—		
当期純利益（△：損失） Net income(Δ:loss)	403	6,295	6,151	5,748	1,423.8%	△ 143	△ 2.3%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	△ 84	974	783	867	—	△ 190	△ 19.5%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	487	5,321	5,368	4,880	1,000.5%	47	0.9%
設備投資額（有形・無形） Capital expenditures	2,802	1,025	844	△ 1,958	△ 69.9%	△ 180	△ 17.7%
減価償却費（有形・無形） Depreciation and Amortization	1,430	1,637	1,675	244	17.1%	37	2.3%
のれん償却額 Amortization of goodwill	379	385	374	△ 4	△ 1.1%	△ 10	△ 2.7%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2021年3月期 FY2021	2022年3月期 FY2022/ Apr. 1, 2021 - Mar. 31, 2022		対前期 Change from FY2021		対2/10予想 Change from forecast anounced Feb. 2022	
	実績 Actual (a)	2/10予想 Forecast announced Feb. 10, 2022 (b)	実績 Actual (c)	増減 Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減 Difference (c-b)	率(c/b-1) YOY% (c/b-1)
試薬 Reagents	35,189	52,213	54,605	19,416	55.2%	2,392	4.6%
機器 Instruments	1,726	1,354	1,518	△ 208	△ 12.1%	163	12.1%
受託 CDMO	8,901	11,283	11,426	2,525	28.4%	143	1.3%
遺伝子医療 Gene Therapy	268	148	148	△ 119	△ 44.5%	△ 0	△ 0.0%
売上高 Net sales	46,086	65,000	67,699	21,613	46.9%	2,699	4.2%
売上原価 Cost of sales	14,214	18,524	18,488	4,274	30.1%	△ 35	△ 0.2%
売上総利益 Gross profit	31,872	46,475	49,211	17,339	54.4%	2,735	5.9%
運送費、保管料 Transportation and storage	742	865	755	13	1.8%	△ 109	△ 12.7%
広告宣伝費 Advertising	57	58	58	0	1.4%	—	—
販売促進費 Sales promotion	676	683	683	7	1.1%	0	0.1%
研究開発費 Research and development	5,545	6,162	6,109	564	10.2%	△ 52	△ 0.8%
管理費、その他 Other, net	10,897	12,707	12,702	1,804	16.6%	△ 4	△ 0.0%
販売費及び一般管理費 SG&A expenses	17,919	20,475	20,309	2,390	13.3%	△ 166	△ 0.8%
営業利益（△：損失） Operating income(Δ:loss)	13,952	26,000	28,902	14,949	107.1%	2,902	11.2%
営業外収益 Non-operating income	308	293	357	49	16.2%	64	21.9%
営業外費用 Non-operating expenses	101	93	800	699	691.6%	706	756.7%
経常利益（△：損失） Ordinary income(Δ:loss)	14,159	26,200	28,459	14,299	101.0%	2,259	8.6%
特別利益 Extraordinary income	518	4,821	4,476	3,957	763.2%	△ 345	△ 7.2%
特別損失 Extraordinary loss	1,125	4,925	5,403	4,278	380.1%	477	9.7%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	13,552	26,095	27,532	13,979	103.1%	1,436	5.5%
法人税、住民税及び事業税 Current income taxes	4,297	7,536	7,901	3,603	83.8%	87	1.2%
法人税等調整額 Deferred income taxes	△ 326		△ 277	49	—		
当期純利益（△：損失） Net income(Δ:loss)	9,581	18,559	19,908	10,326	107.8%	1,348	7.3%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	34	59	58	23	69.9%	△ 1	△ 1.7%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	9,547	18,500	19,849	10,302	107.9%	1,349	7.3%
設備投資額（有形・無形） Capital expenditures	8,897	14,795	13,180	4,283	48.1%	△ 1,614	△ 10.9%
減価償却費（有形・無形） Depreciation and Amortization	3,220	3,534	3,554	334	10.4%	20	0.6%
のれん償却額 Amortization of goodwill	486	500	500	14	2.9%	0	0.1%

5. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		2017年3月期 FY2017	2018年3月期 FY2018	2019年3月期 FY2019	2020年3月期 FY2020	2021年3月期 FY2021	2022年3月期 FY2022	前期対比 Change from FY2021 増減 Change	前期対比 Change from FY2021 率 YOY%
売上高	Net sales	234,193	268,142	277,443	281,191	278,443	300,918	22,474	8.1%
売上原価	Cost of sales	140,182	163,529	168,694	172,574	162,849	187,376	24,527	15.1%
（売上高原価率）	(Ratio to Net sales)	59.9%	61.0%	60.8%	61.4%	58.5%	62.3%	+3.8pt	6.5%
売上総利益	Gross profit	94,010	104,612	108,749	108,617	115,594	113,541	△ 2,052	△ 1.8%
販売費及び一般管理費	SG&A expenses	80,458	88,999	90,945	92,781	93,999	70,187	△ 23,811	△ 25.3%
（売上高販管費率）	(Ratio to Net sales)	34.4%	33.2%	32.8%	33.0%	33.8%	23.3%	-10.4pt	△ 30.9%
営業利益（△：損失）	Operating income(Δ:loss)	13,551	15,612	17,804	15,836	21,595	43,354	21,759	100.8%
（売上高営業利益率）	(Ratio to Net Sales)	5.8%	5.8%	6.4%	5.6%	7.8%	14.4%	+6.7pt	85.8%
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	34,292	33,688	34,012	35,073	34,128	3,883	△ 30,245	△ 88.6%
（売上高販促費率）	(Ratio to Net sales)	14.6%	12.6%	12.3%	12.5%	12.3%	1.3%	-11.0pt	△ 89.5%
研究開発費	R&D expenses	4,550	5,063	4,708	4,259	5,914	6,484	570	9.6%
（売上高研究開発費率）	(Ratio to Net sales)	1.9%	1.9%	1.7%	1.5%	2.1%	2.2%	+0.0pt	1.5%
設備投資額（有形・無形）	Capital expenditures	6,658	6,414	10,671	14,195	13,775	16,213	2,438	17.7%
減価償却費（有形・無形）	Depreciation and Amortization	5,171	6,430	6,490	7,626	8,068	8,425	356	4.4%
のれん償却額	Amortization of goodwill	586	843	865	847	865	875	9	1.2%

宝酒造 :Takara Shuzo

（百万円 :Millions of Yen）

		2017年3月期 FY2017	2018年3月期 FY2018	2019年3月期 FY2019	2020年3月期 FY2020	2021年3月期 FY2021	2022年3月期 FY2022	前期対比 Change from FY2021 増減 Change	前期対比 Change from FY2021 率 YOY%
売上高	Net sales	149,452	149,839	152,457	153,141	152,537	119,710	△ 32,827	△ 21.5%
売上原価	Cost of sales	89,278	89,681	91,441	92,822	92,439	90,898	△ 1,540	△ 1.7%
（売上高原価率）	(Ratio to Net sales)	59.7%	59.9%	60.0%	60.6%	60.6%	75.9%	+15.3pt	25.3%
売上総利益	Gross profit	60,174	60,158	61,015	60,318	60,098	28,811	△ 31,286	△ 52.1%
販売費及び一般管理費	SG&A expenses	55,103	54,589	55,067	56,142	55,218	24,676	△ 30,542	△ 55.3%
（売上高販管費率）	(Ratio to Net sales)	36.9%	36.4%	36.1%	36.7%	36.2%	20.6%	-15.6pt	△ 43.1%
営業利益（△：損失）	Operating income(Δ:loss)	5,071	5,569	5,948	4,175	4,879	4,135	△ 743	△ 15.2%
（売上高営業利益率）	(Ratio to Net sales)	3.4%	3.7%	3.9%	2.7%	3.2%	3.5%	+0.3pt	8.0%
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	32,923	32,342	32,658	33,844	32,981	2,423	△ 30,558	△ 92.7%
（売上高販促費率）	(Ratio to Net sales)	22.0%	21.6%	21.4%	22.1%	21.6%	2.0%	-19.6pt	△ 90.6%
設備投資額（有形・無形）	Capital expenditures	2,188	2,696	3,128	5,520	1,430	1,785	354	24.8%
減価償却費（有形・無形）	Depreciation and Amortization	2,196	2,225	2,248	2,736	2,848	2,590	△ 257	△ 9.1%

宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

		2017年3月期 FY2017	2018年3月期 FY2018	2019年3月期 FY2019	2020年3月期 FY2020	2021年3月期 FY2021	2022年3月期 FY2022	前期対比 Change from FY2021 増減 Change	前期対比 Change from FY2021 率 YOY%
売上高	Net sales	37,540	70,717	77,834	82,765	69,589	102,186	32,596	46.8%
売上原価	Cost of sales	25,641	49,843	54,823	58,882	48,983	70,045	21,061	43.0%
（売上高原価率）	(Ratio to Net sales)	68.3%	70.5%	70.4%	71.1%	70.4%	68.5%	-1.8pt	△ 2.6%
売上総利益	Gross profit	11,899	20,874	23,010	23,883	20,605	32,140	11,535	56.0%
販売費及び一般管理費	SG&A expenses	8,716	16,480	18,478	20,351	19,562	23,667	4,105	21.0%
（売上高販管費率）	(Ratio to Net sales)	23.2%	23.3%	23.7%	24.6%	28.1%	23.2%	-4.9pt	△ 17.6%
営業利益（△：損失）	Operating income(Δ:loss)	3,182	4,393	4,532	3,532	1,043	8,472	7,429	712.1%
（売上高営業利益率）	(Ratio to Net sales)	8.5%	6.2%	5.8%	4.3%	1.5%	8.3%	+6.8pt	453.1%
設備投資額（有形・無形）	Capital expenditures	763	1,677	1,162	2,696	2,802	844	△ 1,958	△ 69.9%
減価償却費（有形・無形）	Depreciation and Amortization	623	938	1,013	1,434	1,430	1,675	244	17.1%
のれん償却額	Amortization of goodwill	424	353	362	350	379	374	△ 4	△ 1.1%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		2017年3月期 FY2017	2018年3月期 FY2018	2019年3月期 FY2019	2020年3月期 FY2020	2021年3月期 FY2021	2022年3月期 FY2022	前期対比 Change from FY2021 増減 Change	前期対比 Change from FY2021 率 YOY%
売上高	Net sales	29,375	32,312	35,841	34,565	46,086	67,699	21,613	146.9%
売上原価	Cost of sales	12,422	13,657	15,155	13,459	14,214	18,488	4,274	130.1%
（売上高原価率）	(Ratio to Net sales)	42.3%	42.3%	42.3%	38.9%	30.8%	27.3%	-3.5pt	—
売上総利益	Gross profit	16,952	18,655	20,685	21,105	31,872	49,211	17,339	154.4%
販売費及び一般管理費	SG&A expenses	13,749	15,099	15,221	14,830	17,919	20,309	2,390	113.3%
（売上高販管費率）	(Ratio to Net sales)	46.8%	46.7%	42.5%	42.9%	38.9%	30.0%	-8.9pt	—
営業利益（△：損失）	Operating income(Δ:loss)	3,202	3,555	5,463	6,274	13,952	28,902	14,949	207.1%
（売上高営業利益率）	(Ratio to Net sales)	10.9%	11.0%	15.2%	18.2%	30.3%	42.7%	+12.4pt	—
研究開発費	R&D expenses	4,101	4,653	4,337	3,869	5,545	6,109	564	110.2%
（売上高研究開発費率）	(Ratio to Net sales)	14.0%	14.4%	12.1%	11.2%	12.0%	9.0%	-3.0pt	—
設備投資額（有形・無形）	Capital expenditures	1,648	1,539	6,002	5,365	8,897	13,180	4,283	148.1%
減価償却費（有形・無形）	Depreciation and Amortization	1,722	2,568	2,691	2,921	3,220	3,554	334	110.4%
のれん償却額	Amortization of goodwill	162	489	502	496	486	500	14	102.9%

6. 2022年3月期 参考資料 :Reference Data for the year ending March 31, 2022

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用):Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2021年3月期 Jan. 1, 2020 - Dec.31, 2020	2022年3月期 Jan. 1, 2021 - Dec.31, 2021			
	実績 Actual (a)	2/10予想 Forecast announced Feb. 2022 (b)	実績 Actual (c)	前期差 Change(c-a)	予想差 Difference(c-b)
米ドル : US dollar	106.77	109.90	109.90	3.13	0.00
ポンド: Pound	137.02	151.17	151.17	14.15	0.00
ユーロ: Euro	121.88	129.91	129.91	8.03	0.00
人民元: Yuan	15.48	17.04	17.04	1.56	0.00
100ウォン: 100 Won	9.06	9.60	9.60	0.54	0.00
インドルピー: Rupee	1.44	1.49	1.49	0.05	0.00
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	11.63	12.81	12.81	1.18	0.00
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	77.43	81.77	81.77	4.34	0.00
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	73.69	82.50	82.50	8.81	0.00

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2021
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	7,014
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ 計 Net sales of Takara Shuzo International Group	5,008
海外酒類事業 Overseas Alcoholic beverages business	709
海外日本食材卸事業 Japanese food wholesale business in overseas markets	4,359
その他および調整額 Other / Adjustment	△ 60
タカラバイオグループ 計 Net sales of Takara Bio Group	2,005
試薬 Reagents	1,930
理化学機器 Instruments	18
受託サービス CDMO	57
遺伝子医療 Gene Therapy	―

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2021年3月期 実績 FY2021 Actual			2022年3月期 実績 FY2022 Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	152,537	―	―	119,710	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	69,589	69,287	99.6%	102,186	101,767	99.6%
タカラバイオグループ Takara Bio Group	46,086	25,611	55.6%	67,699	33,623	49.7%
その他および調整額 Other / Adjustment	10,230	―	―	11,322	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	278,443	94,898	34.1%	300,918	135,390	45.0%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2021年3月期 FY2021 Actual		2022年3月期 実績 FY2022 Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	27,554	552	40,704	5,887
Takara Sake USA Inc.	百 万 円 :Millions of Yen	2,941	58	4,473	647
宝酒造食品	千 元 :Thousands of Yuan	44,014	1,292	62,563	4,407
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	681	20	1,066	75
トマーチン	千 ポ ン ド :Thousands of Pound	19,677	6,422	25,392	9,076
The Tomatin Distillery Co.,Ltd	百 万 円 :Millions of Yen	2,696	880	3,838	1,372
ｴｲｼﾞ･ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	30,737	14,068	36,953	16,934
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	3,281	1,502	4,061	1,861
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	161,182	11,945	226,841	23,558
FOODEX Group	百 万 円 :Millions of Yen	19,644	1,455	29,469	3,060
タザキフーズ	千 ポ ン ド :Thousands of Pound	40,987	1,539	53,010	2,227
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	5,616	210	8,013	336
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	283,226	△ 16,690	418,794	16,258
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	30,240	△ 1,782	46,025	1,786
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	51,524	2,336	54,177	4,040
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	3,796	172	4,469	333
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	6,802	266	11,679	645
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S. (連結)	千 ユ ー ロ :Thousands of Euro	51,919	8,959	63,735	11,850
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	6,327	1,091	8,279	1,539
宝生物工程(大連)	千 元 :Thousands of Yuan	343,768	159,774	289,944	81,664
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	5,321	2,473	4,940	1,391
宝日医生物技術(北京)	千 元 :Thousands of Yuan	537,673	97,101	692,533	111,892
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	8,323	1,503	11,800	1,906
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	12,605	2,123	12,807	2,059
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	1,142	192	1,229	197
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	460,020	63,490	676,136	99,845
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	662	91	1,007	148
タカラバイオUSA	千 US ドル :Thousands of US dollar	102,682	5,386	124,580	17,591
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	10,963	575	13,691	1,933

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2021			
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition	収益認識 Effect of applying "Accounting Standards for Revenue Recognition"
売上総利益 計 Gross profit	△ 31,286	△ 1,507	△ 778	△ 29,000
(主な内訳)				
焼酎 Shochu	△ 10,281	△ 420	△ 274	△ 9,585
清酒 Sake	△ 3,975	△ 623	+4	△ 3,356
ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers	△ 9,225	△ 303	△ 159	△ 8,762
本みりん Hon Mirin	△ 4,531	+109	△ 166	△ 4,474
(参考)原価コストダウン Reference :Cost reduction	△ 838	※上記構成差に含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

(百万円 :Millions of Yen)

	2021年3月期 FY2021 Actual		2022年3月期 実績 FY2022 Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	13,703	563	13,904	613
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	506	416	502	416
その他 Other	15,027	823	16,312	1,192
「その他」計 Total "Other"	29,238	1,803	30,719	2,222

7. 2022年3月期 業績【「収益認識に関する会計基準」等適用前】

Results for the year ended March 31, 2022 based on before the application of 【Accounting Standard for Revenue Recognition】

①宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 Millions of Yen)

	2021年3月期 累計	2022年3月期 累計 Apr. 1, 2021 - Mar. 31, 2022		
	実績(a) FY2021 Actual (a)	実績(b) FY2022 Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
宝酒造 Takara Shuzo	152,537	148,710	△ 3,826	△ 2.5%
宝酒造インターナショナルグループ Takara Shuzo International Group	69,589	102,214	32,625	46.9%
タカラバイオ グループ Takara Bio Group	46,086	67,699	21,613	46.9%
その他 Other	29,238	30,719	1,481	5.1%
調整額 Adjustment	△ 19,007	△ 19,396	△ 389	―
売上高 Net sales	278,443	329,947	51,503	18.5%
売上原価 Cost of sales	162,849	187,376	24,527	15.1%
売上総利益 Gross profit	115,594	142,570	26,975	23.3%
運送費、保管料 Transportation and storage	10,937	12,076	1,139	10.4%
広告宣伝費 Advertising	2,251	2,510	259	11.5%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	34,128	32,911	△ 1,216	△ 3.6%
研究開発費 Research and development	5,914	6,484	570	9.6%
管理費、その他 Other, net	40,768	45,232	4,464	11.0%
販売費及び一般管理費 SG&A expenses	93,999	99,216	5,216	5.5%
宝酒造 Takara Shuzo	4,879	4,135	△ 743	△ 15.2%
宝酒造インターナショナルグループ Takara Shuzo International Group	1,043	8,472	7,429	712.1%
タカラバイオ グループ Takara Bio Group	13,952	28,902	14,949	107.1%
その他 Other	1,803	2,222	419	23.2%
調整額 Adjustment	△ 84	△ 379	△ 295	―
営業利益(△:損失) Operating income(Δ:loss)	21,595	43,354	21,759	100.8%
受取利息・配当金 Interest and Dividends income	707	767	59	8.5%
その他営業外収益 Other, net	603	725	121	20.1%
営業外収益 Non-operating income	1,311	1,492	181	13.8%
支払利息 Interest and discounts expenses	344	330	△ 13	△ 3.9%
その他営業外費用 Other, net	632	1,284	652	103.3%
営業外費用 Non-operating expenses	976	1,615	639	65.5%
経常利益(△:損失) Ordinary income(Δ:loss)	21,929	43,230	21,300	97.1%
特別利益 Extraordinary income	529	4,658	4,129	780.5%
特別損失 Extraordinary loss	1,875	6,928	5,052	269.4%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	20,583	40,961	20,377	99.0%
法人税、住民税及び事業税 Current income taxes	6,303	11,900	5,596	88.8%
法人税等調整額 Deferred income taxes	23	△ 309	△ 332	―
当期純利益(△:損失) Net income(Δ:loss)	14,256	29,370	15,113	106.0%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	3,682	8,601	4,918	133.6%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	10,574	20,769	10,194	96.4%
設備投資額(有形・無形) Capital expenditures	13,775	16,213	2,438	17.7%
減価償却費(有形・無形) Depreciation and Amortization	8,068	8,425	356	4.4%
のれん償却額 Amortization of goodwill	865	875	9	1.2%

②宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

	2021年3月期 累計	2022年3月期 累計 Apr. 1, 2021 - Mar. 31, 2022		
	実績(a) FY2021 Actual (a)	実績(b) FY2022 Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
焼酎 Shochu	48,631	47,521	△ 1,109	△ 2.3%
清酒 Sake	17,706	16,160	△ 1,546	△ 8.7%
ソフトアルコール飲料 Light-alcohol refreshers	47,154	46,439	△ 714	△ 1.5%
その他酒類 Other liquors	5,573	6,123	550	9.9%
本みりん Hon Mirin	13,367	13,571	204	1.5%
その他調味料 Other seasonings	10,441	10,712	270	2.6%
原料用アルコール等 Raw alcohol	9,663	8,181	△ 1,481	△ 15.3%
売上高 Net sales	152,537	148,710	△ 3,826	△ 2.5%
売上原価 Cost of sales	92,439	90,898	△ 1,540	△ 1.7%
売上総利益 Gross profit	60,098	57,811	△ 2,286	△ 3.8%
運送費、保管料 Transportation and storage	8,173	8,134	△ 39	△ 0.5%
広告宣伝費 Advertising	2,089	2,327	238	11.4%
販売促進費 Sales promotion	32,981	31,423	△ 1,558	△ 4.7%
研究開発費 Research and development	363	366	2	0.6%
管理費、その他 Other, net	11,610	11,425	△ 185	△ 1.6%
販売費及び一般管理費 SG&A expenses	55,218	53,676	△ 1,542	△ 2.8%
営業利益(△:損失) Operating income(Δ:loss)	4,879	4,135	△ 743	△ 15.2%
営業外収益 Non-operating income	239	281	42	17.5%
営業外費用 Non-operating expenses	402	346	△ 55	△ 13.8%
経常利益(△:損失) Ordinary income(Δ:loss)	4,716	4,070	△ 646	△ 13.7%
特別利益 Extraordinary income	0	110	110	53,775.9%
特別損失 Extraordinary loss	188	1,321	1,133	600.4%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	4,528	2,859	△ 1,668	△ 36.9%
法人税、住民税及び事業税 Current income taxes	1,469	1,007	△ 461	△ 31.4%
法人税等調整額 Deferred income taxes	△ 43	△ 96	△ 52	—
当期純利益(△:損失) Net income(Δ:loss)	3,102	1,948	△ 1,154	△ 37.2%
設備投資額(有形・無形) Capital expenditures	1,430	1,785	354	24.8%
減価償却費(有形・無形) Depreciation and Amortization	2,848	2,590	△ 257	△ 9.1%

③宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

	2021年3月期 累計	2022年3月期 累計 Apr. 1, 2021 - Mar. 31, 2022		
	実績(a) FY2021 Actual (a)	実績(b) FY2022 Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
海外酒類事業 Overseas Alcoholic beverages business	10,100	14,092	3,991	39.5%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	60,431	89,728	29,297	48.5%
その他 Other	57	62	5	8.9%
連結消去 Elimination	△ 999	△ 1,668	△ 669	—
売上高 Net sales	69,589	102,214	32,625	46.9%
売上原価 Cost of sales	48,983	70,045	21,061	43.0%
売上総利益 Gross profit	20,605	32,169	11,563	56.1%
運送費、保管料 Transportation and storage	2,283	3,490	1,206	52.9%
広告宣伝費 Advertising	91	112	20	22.6%
販売促進費 Sales promotion	553	840	287	52.0%
管理費、その他 Other, net	16,634	19,253	2,618	15.7%
販売費及び一般管理費 SG&A expenses	19,562	23,696	4,134	21.1%
海外酒類事業 Overseas Alcoholic beverages business	2,256	3,781	1,525	67.6%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	286	6,112	5,825	2,032.1%
その他 Other	△ 1,042	△ 933	108	—
連結消去 Elimination	△ 457	△ 487	△ 30	—
営業利益(△:損失) Operating income(Δ:loss)	1,043	8,472	7,429	712.1%
営業外収益 Non-operating income	180	297	117	65.3%
営業外費用 Non-operating expenses	318	309	△ 8	△ 2.8%
経常利益(△:損失) Ordinary income(Δ:loss)	904	8,461	7,556	834.9%
特別利益 Extraordinary income	3	3	△ 0	△ 17.7%
特別損失 Extraordinary loss	477	202	△ 274	△ 57.6%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	431	8,261	7,830	1,815.0%
法人税、住民税及び事業税 Current income taxes	△ 7	2,159	2,166	—
法人税等調整額 Deferred income taxes	35	△ 49	△ 84	—
当期純利益(△:損失) Net income(Δ:loss)	403	6,151	5,748	1,423.8%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	△ 84	783	867	—
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	487	5,368	4,880	1,000.5%
設備投資額(有形・無形) Capital expenditures	2,802	844	△ 1,958	△ 69.9%
減価償却費(有形・無形) Depreciation and Amortization	1,430	1,675	244	17.1%
のれん償却額 Amortization of goodwill	379	374	△ 4	△ 1.1%

8. 2023年3月期 業績予想 :Financial forecast for the year ending March 31, 2023

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2022年3月期 通期 実績 FY2022 Actual (a)	2023年3月期 通期 予想 FY2023 Forecast (b)	対前期 Change from FY2022 増減 Change (b-a)	対前期 Change from FY2022 率(b/a-1) YOY% (b/a-1)	2022年3月期 第2四半期累計 実績 FY2022(1Q-2Q) Actual (c)	2023年3月期 第2四半期累計 予想 FY2023(1Q-2Q) Forecast (d)	対前期 Change from FY2022(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2022(1Q-2Q) 率(d/c-1) YOY% (d/c-1)
宝酒造 Takara Shuzo	119,710	120,377	666	0.6%	57,633	58,350	716	1.2%
宝酒造インターナショナルグループ Takara Shuzo International Group	102,186	114,035	11,848	11.6%	46,734	54,336	7,601	16.3%
タカラバイオ グループ Takara Bio Group	67,699	55,300	△ 12,399	△ 18.3%	31,551	27,744	△ 3,806	△ 12.1%
その他 Other	30,719	30,972	252	0.8%	14,624	15,018	393	2.7%
調整額 Adjustment	△ 19,396	△ 19,684	△ 287	—	△ 9,331	△ 9,448	△ 117	—
売上高 Net sales	300,918	301,000	81	0.0%	141,213	146,000	4,786	3.4%
売上原価 Cost of sales	187,376	193,700	6,323	3.4%	86,872	93,400	6,527	7.5%
売上総利益 Gross profit	113,541	107,300	△ 6,241	△ 5.5%	54,340	52,600	△ 1,740	△ 3.2%
運送費、保管料 Transportation and storage	12,076	12,700	623	5.2%	5,752	6,100	347	6.0%
広告宣伝費 Advertising	2,510	2,700	189	7.5%	1,122	1,500	377	33.6%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	3,883	4,700	816	21.0%	1,697	2,100	402	23.7%
研究開発費 Research and development	6,484	8,200	1,715	26.5%	2,847	3,900	1,052	37.0%
管理費、その他 Other, net	45,232	49,000	3,767	8.3%	21,305	24,000	2,694	12.6%
販売費及び一般管理費 SG&A expenses	70,187	77,300	7,112	10.1%	32,724	37,600	4,875	14.9%
宝酒造 Takara Shuzo	4,135	4,234	98	2.4%	2,270	1,332	△ 938	△ 41.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	8,472	9,100	627	7.4%	4,304	4,336	31	0.7%
タカラバイオ グループ Takara Bio Group	28,902	15,000	△ 13,902	△ 48.1%	14,105	8,641	△ 5,463	△ 38.7%
その他 Other	2,222	2,270	47	2.1%	1,029	1,073	43	4.2%
調整額 Adjustment	△ 379	△ 603	△ 224	—	△ 93	△ 382	△ 289	—
営業利益(△:損失) Operating income(Δ:loss)	43,354	30,000	△ 13,354	△ 30.8%	21,616	15,000	△ 6,616	△ 30.6%
受取利息・配当金 Interest and Dividends income	767	800	32	4.3%	381	400	18	4.9%
その他営業外収益 Other, net	725	200	△ 525	△ 72.4%	287	200	△ 87	△ 30.5%
営業外収益 Non-operating income	1,492	1,000	△ 492	△ 33.0%	669	600	△ 69	△ 10.3%
支払利息 Interest and discounts expenses	330	200	△ 130	△ 39.6%	160	100	△ 60	△ 37.8%
その他営業外費用 Other, net	1,284	400	△ 884	△ 68.9%	239	100	△ 139	△ 58.3%
営業外費用 Non-operating expenses	1,615	600	△ 1,015	△ 62.9%	400	200	△ 200	△ 50.1%
経常利益(△:損失) Ordinary income(Δ:loss)	43,230	30,400	△ 12,830	△ 29.7%	21,884	15,400	△ 6,484	△ 29.6%
特別利益 Extraordinary gain	4,658	250	△ 4,408	△ 94.6%	1,368	250	△ 1,118	△ 81.7%
特別損失 Extraordinary loss	6,928	150	△ 6,778	△ 97.8%	2,853	50	△ 2,803	△ 98.2%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	40,961	30,500	△ 10,461	△ 25.5%	20,400	15,600	△ 4,800	△ 23.5%
法人税、住民税及び事業税 Current income taxes	11,900	9,400	△ 2,190	△ 18.9%	6,396	4,600	△ 1,441	△ 23.9%
法人税等調整額 Deferred income taxes	△ 309				△ 354			
当期純利益(△:損失) Net income(Δ:loss)	29,370	21,100	△ 8,270	△ 28.2%	14,358	11,000	△ 3,358	△ 23.4%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	8,601	5,100	△ 3,501	△ 40.7%	4,308	2,900	△ 1,408	△ 32.7%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent	20,769	16,000	△ 4,769	△ 23.0%	10,050	8,100	△ 1,950	△ 19.4%
設備投資額(有形・無形) Capital expenditures	16,213	16,395	181	1.1%	8,811			
減価償却費(有形・無形) Depreciation and Amortization	8,425	9,200	774	9.2%	4,061	4,500	438	10.8%
のれん償却額 Amortization of goodwill	875	800	△ 75	△ 8.6%	432	400	△ 32	△ 7.5%

② 宝酒造 :Takara Shuzo

（百万円 :Millions of Yen）

	2022年3月期 通期 実績 FY2022 Actual (a)	2023年3月期 通期 予想 FY2023 Forecast (b)	対前期 Change from FY2022 増減 Change (b-a)	対前期 Change from FY2022 率(b/a-1) YOY% (b/a-1)	2022年3月期 第2四半期累計 実績 FY2022(1Q-2Q) Actual (c)	2023年3月期 第2四半期累計 予想 FY2023(1Q-2Q) Forecast (d)	対前期 Change from FY2022(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2022(1Q-2Q) 率(d/c-1) YOY% (d/c-1)
焼酎 Shochu	37,935	35,370	△ 2,565	△ 6.8%	19,315	18,389	△ 926	△ 4.8%
清酒 Sake	12,803	12,782	△ 21	△ 0.2%	4,718	4,730	11	0.2%
ソフトアルコール飲料 Light-alcohol refreshers	37,677	41,632	3,954	10.5%	18,808	20,793	1,984	10.5%
その他酒類 Other liquors	5,467	5,291	△ 176	△ 3.2%	2,529	2,388	△ 141	△ 5.6%
本みりん Hon Mirin	9,097	9,003	△ 94	△ 1.0%	4,258	4,257	△ 1	△ 0.0%
その他調味料 Other seasonings	8,560	8,769	208	2.4%	4,079	4,200	120	3.0%
原料用アルコール等 Raw alcohol	8,168	7,529	△ 639	△ 7.8%	3,922	3,593	△ 329	△ 8.4%
売上高 Net sales	119,710	120,377	666	0.6%	57,633	58,350	716	1.2%
売上原価 Cost of sales	90,898	90,781	△ 117	△ 0.1%	43,341	44,501	1,159	2.7%
売上総利益 Gross profit	28,811	29,596	784	2.7%	14,291	13,849	△ 442	△ 3.1%
運送費、保管料 Transportation and storage	8,134	8,337	202	2.5%	3,977	4,050	72	1.8%
広告宣伝費 Advertising	2,327	2,544	216	9.3%	1,052	1,439	386	36.8%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	2,423	2,943	519	21.5%	1,059	1,242	182	17.2%
研究開発費 Research and development	366	379	12	3.5%	183	187	3	2.0%
管理費、その他 Other, net	11,425	11,159	△ 266	△ 2.3%	5,748	5,599	△ 149	△ 2.6%
販売費及び一般管理費 SG&A expenses	24,676	25,362	685	2.8%	12,020	12,517	496	4.1%
営業利益（△：損失） Operating income(Δ:loss)	4,135	4,234	98	2.4%	2,270	1,332	△ 938	△ 41.3%
営業外収益 Non-operating income	281	339	57	20.3%	178	261	82	46.5%
営業外費用 Non-operating expenses	346	276	△ 70	△ 20.4%	127	119	△ 8	△ 6.8%
経常利益（△：損失） Ordinary income(Δ:loss)	4,070	4,297	226	5.6%	2,321	1,474	△ 847	△ 36.5%
特別利益 Extraordinary gain	110	—	△ 110	—	110	—	△ 110	—
特別損失 Extraordinary loss	1,321	169	△ 1,152	△ 87.2%	1,622	30	△ 1,592	△ 98.2%
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	2,859	4,128	1,268	44.4%	809	1,444	634	78.4%
法人税等 Current income taxes, etc.	1,007	1,416	504	55.4%	459	464	207	80.8%
法人税等調整額 Deferred income taxes	△ 96				△ 202			
当期純利益（△：損失） Net income(Δ:loss)	1,948	2,712	763	39.2%	552	980	427	77.3%
設備投資額（有形・無形） Capital expenditures	1,785	4,008	2,222	124.5%	500			
減価償却費（有形・無形） Depreciation and Amortization	2,590	2,582	△ 8	△ 0.3%	1,257	1,241	△ 16	△ 1.3%

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

	2022年3月期 通期 実績 FY2022 Actual (a)	2023年3月期 通期 予想 FY2023 Forecast (b)	対前期 Change from FY2022 増減 Change (b-a)	対前期 Change from FY2022 率(b/a-1) YOY% (b/a-1)	2022年3月期 第2四半期累計 実績 FY2022(1Q-2Q) Actual (c)	2023年3月期 第2四半期累計 予想 FY2023(1Q-2Q) Forecast (d)	対前期 Change from FY2022(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2022(1Q-2Q) 率(d/c-1) YOY% (d/c-1)
海外酒類事業 Overseas Alcoholic beverages business	14,063	15,450	1,386	9.9%	7,005	7,285	279	4.0%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	89,728	100,364	10,635	11.9%	40,410	47,942	7,531	18.6%
その他 Other	62	2,468	2,405	3,865.0%	29	2,439	2,409	8,105.2%
連結消去 Elimination	△ 1,668	△ 4,247	△ 2,578	—	△ 710	△ 3,330	△ 2,619	—
売上高 Net sales	102,186	114,035	11,848	11.6%	46,734	54,336	7,601	16.3%
売上原価 Cost of sales	70,045	77,719	7,673	11.0%	31,747	36,942	5,194	16.4%
売上総利益 Gross profit	32,140	36,316	4,175	13.0%	14,987	17,394	2,406	16.1%
運送費、保管料 Transportation and storage	3,490	3,833	342	9.8%	1,517	1,833	315	20.8%
広告宣伝費 Advertising	112	142	29	26.5%	39	62	22	56.2%
販売促進費 Sales promotion	812	972	159	19.6%	355	425	69	19.4%
管理費、その他 Other, net	19,253	22,269	3,015	15.7%	8,769	10,738	1,968	22.4%
販売費及び一般管理費 SG&A expenses	23,667	27,216	3,548	15.0%	10,682	13,058	2,375	22.2%
海外酒類事業 Overseas Alcoholic beverages business	3,781	4,331	549	14.5%	2,145	2,117	△ 28	△ 1.3%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	6,112	6,515	402	6.6%	2,904	3,001	96	3.3%
その他 Other	△ 933	1,161	2,094	—	△ 491	1,870	2,361	—
連結消去 Elimination	△ 487	△ 2,907	△ 2,419	—	△ 254	△ 2,652	△ 2,397	—
営業利益（△：損失） Operating income(Δ:loss)	8,472	9,100	627	7.4%	4,304	4,336	31	0.7%
営業外収益 Non-operating income	297	102	△ 195	△ 65.7%	81	35	△ 46	△ 57.2%
営業外費用 Non-operating expenses	309	158	△ 151	△ 48.9%	159	77	△ 82	△ 51.7%
経常利益（△：損失） Ordinary income(Δ:loss)	8,461	9,044	582	6.9%	4,226	4,294	67	1.6%
特別利益 Extraordinary gain	3	—	△ 3	—	2	—	△ 2	—
特別損失 Extraordinary loss	202	2	△ 200	△ 99.0%	6	1	△ 5	△ 84.2%
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	8,261	9,042	780	9.4%	4,222	4,293	70	1.7%
法人税等 Current income taxes, etc.	2,159	2,568	458	21.7%	1,108	1,204	40	3.5%
法人税等調整額 Deferred income taxes	△ 49				55			
当期純利益（△：損失） Net income(Δ:loss)	6,151	6,474	322	5.2%	3,059	3,089	29	1.0%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	783	870	86	11.0%	349	377	27	7.8%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent	5,368	5,604	235	4.4%	2,709	2,712	2	0.1%
設備投資額（有形・無形） Capital expenditures	844	2,111	1,266	150.1%	462			
減価償却費（有形・無形） Depreciation and Amortization	1,675	1,824	148	8.9%	837	897	59	7.1%
のれん償却額 Amortization of goodwill	374	370	△ 4	△ 1.3%	187	185	△ 2	△ 1.1%

④ タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

	2022年3月期 通期 実績 FY2022 Actual (a)	2023年3月期 通期 予想 FY2023 Forecast (b)	対前期 Change from FY2022 増減 Change (b-a)	対前期 Change from FY2022 率(b/a-1) YOY% (b/a-1)	2022年3月期 第2四半期累計 実績 FY2022(1Q-2Q) Actual (c)	2023年3月期 第2四半期累計 予想 FY2023(1Q-2Q) Forecast (d)	対前期 Change from FY2022(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2022(1Q-2Q) 率(d/c-1) YOY% (d/c-1)
試薬 Reagents	52,479	41,010	△ 11,468	△ 21.9%	25,966	22,576	△ 3,390	△ 13.1%
機器 Instruments	1,518	1,471	△ 47	△ 3.1%	712	669	△ 43	△ 6.1%
受託 CDMO	11,426	10,212	△ 1,214	△ 10.6%	4,732	3,304	△ 1,427	△ 30.2%
遺伝子医療 Gene Therapy	2,275	2,606	331	14.6%	140	1,194	1,054	751.7%
売上高 Net sales	67,699	55,300	△ 12,399	△ 18.3%	31,551	27,744	△ 3,806	△ 12.1%
売上原価 Cost of sales	18,488	17,444	△ 1,044	△ 5.6%	8,056	8,057	1	0.0%
売上総利益 Gross profit	49,211	37,855	△ 11,355	△ 23.1%	23,495	19,686	△ 3,808	△ 16.2%
運送費、保管料 Transportation and storage	755	748	△ 7	△ 0.9%	406	367	△ 38	△ 9.6%
広告宣伝費 Advertising	58	91	33	56.8%	28	40	11	41.8%
販売促進費 Sales promotion	683	899	215	31.5%	305	457	151	49.6%
研究開発費 Research and development	6,109	7,820	1,711	28.0%	2,659	3,730	1,071	40.3%
管理費、その他 Other, net	12,702	13,295	593	4.7%	5,989	6,448	459	7.7%
販売費及び一般管理費 SG&A expenses	20,309	22,855	2,546	12.5%	9,389	11,044	1,655	17.6%
営業利益（△：損失） Operating income(Δ:loss)	28,902	15,000	△ 13,902	△ 48.1%	14,105	8,641	△ 5,463	△ 38.7%
営業外収益 Non-operating income	357	211	△ 146	△ 40.8%	179	139	△ 39	△ 22.3%
営業外費用 Non-operating expenses	800	111	△ 688	△ 86.0%	43	55	12	28.1%
経常利益（△：損失） Ordinary income(Δ:loss)	28,459	15,100	△ 13,359	△ 46.9%	14,241	8,726	△ 5,515	△ 38.7%
特別利益 Extraordinary gain	4,476	250	△ 4,226	△ 94.4%	1,188	250	△ 938	△ 79.0%
特別損失 Extraordinary loss	5,403	55	△ 5,347	△ 99.0%	1,227	4	△ 1,222	△ 99.6%
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	27,532	15,294	△ 12,237	△ 44.4%	14,203	8,971	△ 5,231	△ 36.8%
法人税等 Current income taxes, etc.	7,901	4,648	△ 2,975	△ 39.0%	4,401	2,588	△ 1,559	△ 37.6%
法人税等調整額 Deferred income taxes	△ 277				△ 253			
当期純利益（△：損失） Net income(Δ:loss)	19,908	10,645	△ 9,262	△ 46.5%	10,054	6,383	△ 3,671	△ 36.5%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	58	45	△ 12	△ 21.4%	45	29	△ 16	△ 36.7%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent	19,849	10,600	△ 9,249	△ 46.6%	10,009	6,354	△ 3,654	△ 36.5%
設備投資額（有形・無形） Capital expenditures	13,180	10,029	△ 3,151	△ 23.9%	7,676			
減価償却費（有形・無形） Depreciation and Amortization	3,554	4,282	727	20.5%	1,670	2,043	372	22.3%
のれん償却額 Amortization of goodwill	500	514	14	2.8%	245	257	11	4.8%

(注)2022年3月期まで「試薬」に含めていたGMPグレード（再生医療等製品製造用）の試薬類等の売上高を、2023年3月期より「遺伝子医療」に加えております。
本表の2022年3月期実績は、当該変更を反映して組み替えております。

9. 2023年3月期 参考資料 :Reference Data for the year ending March 31, 2023

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用):Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2022年3月期 Jan. 1, 2021 - Dec.31, 2021	2023年3月期 Jan. 1, 2022 - Dec.31, 2022	
	実績 Actual (a)	予想 Forecast announced Feb. 2022 (b)	前期差 Change(b-a)
米ドル : US dollar	109.90	113.00	3.10
ポンド: Pound	151.17	152.00	0.83
ユーロ: Euro	129.91	129.00	△ 0.91
人民元: Yuan	17.04	17.30	0.26
100ウォン: 100 Won	9.60	9.60	0.00
インドルピー: Rupee	1.49	1.50	0.01
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	12.81	13.00	0.19
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	81.77	83.60	1.83
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	82.50	84.10	1.60

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2022
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	2,076
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ計 Net sales of Takara Shuzo International Group	1,624
海外酒類事業 Overseas Alcoholic beverages business	295
海外日本食材卸事業 Japanese food wholesale business in overseas markets	1,382
その他および調整額 Other / Adjustment	△ 53
タカラバイオグループ 計 Net sales of Takara Bio Group	452
試薬 Reagents	432
理化学機器 Instruments	10
受託サービス CDMO	10
遺伝子医療 Gene Therapy	―

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2022年3月期通期実績 FY2022 Actual			2023年3月期通期予想 FY2023 Forecast		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	119,710	―	―	120,377	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	102,186	101,767	99.6%	114,035	113,677	99.7%
タカラバイオグループ Takara Bio Group	67,699	33,623	49.7%	55,300	30,150	54.5%
その他および調整額 Other / Adjustment	11,322	―	―	11,288	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	300,918	135,390	45.0%	301,000	143,828	47.8%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2022年3月期 FY2022 Actual		2023年3月期 予想 FY2023 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	40,704	5,887	42,889	6,028
Takara Sake USA Inc.	百 万 円 :Millions of Yen	4,473	647	4,846	681
宝酒造食品	千 元 :Thousands of Yuan	62,563	4,407	67,284	4,437
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	1,066	75	1,164	76
トマーチン	千 ポ ン ド :Thousands of Pound	25,392	9,076	29,658	11,031
The Tomatin Distillery Co.,Ltd	百 万 円 :Millions of Yen	3,838	1,372	4,508	1,676
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	36,953	16,934	38,001	16,960
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	4,061	1,861	4,294	1,916
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	226,841	23,558	242,254	25,000
FOODEX Group	百 万 円 :Millions of Yen	29,469	3,060	31,250	3,225
タザキフーズ	千 ポ ン ド :Thousands of Pound	53,010	2,227	60,000	2,400
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	8,013	336	9,120	364
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	418,794	16,258	470,765	17,299
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	46,025	1,786	53,196	1,954
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	54,177	4,040	58,500	4,287
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	4,469	333	4,919	360
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	11,679	645	12,019	650
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S. (連結)	千 ユ ー ロ :Thousands of Euro	63,735	11,850	47,507	5,854
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	8,279	1,539	6,128	755
宝生物工程(大連)	千 元 :Thousands of Yuan	289,944	81,664	296,051	74,571
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	4,940	1,391	5,121	1,290
宝日医生物技術(北京)	千 元 :Thousands of Yuan	692,533	111,892	566,523	79,049
Takara Biomedical Technology (Beijing) Co., Ltd.	百 万 円 :Millions of Yen	11,800	1,906	9,800	1,367
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	12,807	2,059	14,225	2,224
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	1,229	197	1,365	213
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	676,136	99,845	683,632	78,052
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	1,007	148	1,025	117
タカラバイオUSA	千 US ドル :Thousands of US dollar	124,580	17,591	129,332	17,337
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	13,691	1,933	14,614	1,959

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2022		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	+785	△ 160	+624
(参考)原価コストダウン Reference :Cost reduction	△ 676 ※上記構成差に含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)業績予想(p.13)における「その他」の内訳 :Breakdown of "Other" segment in the Financial forecast of Takara Holdings Inc. (p.13)

(百万円 :Millions of Yen)

	2022年3月期 実績 FY2022 Actual		2023年3月期 予想 FY2023 Forecast	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	13,904	613	14,250	610
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	502	416	506	419
その他 Other	16,312	1,192	16,215	1,240
「その他」計 Total "Other"	30,719	2,222	30,972	2,270